

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 13:18:37 ; Search time 2544 Seconds
(without alignments)
557.662 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattgcgcgaagaagaattgtttctgtc 30

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 4526729 seqs, 23644849745 residues

Total number of hits satisfying chosen parameters: 2024102

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

GenEmbl:

1: gb_da.*
2: gb_htg.*
3: gb_in.*
4: gb_om.*
5: gb_ov.*
6: gb_pat.*
7: gb_ph.*
8: gb_pl.*
9: gb_pr.*
10: gb_ro.*
11: gb_sts.*
12: gb_sy.*
13: gb_un.*
14: gb_vi.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	DB ID	Description
1	30	100.0	30	6	BD237979
2	30	100.0	30	6	AX032823
3	26.8	89.3	30	6	BD237980
4	26.8	89.3	30	6	BD237985
5	26.8	89.3	30	6	BD237989
6	26.8	89.3	30	6	AX032824
7	26.8	89.3	30	6	AX032829
8	26.8	89.3	30	6	AX032833
9	17.2	57.3	30	6	BD237986
10	17.2	57.3	30	6	AX032830
11	17	56.7	43	6	AR411028
12	16.8	56.0	65	11	BX547960
13	16.8	55.3	50	6	AX952037
14	16.6	55.3	50	6	AX952631
15	16.2	54.0	49	6	AX952011
16	16.2	54.0	49	6	AX952044
17	16.2	54.0	49	6	AX952605
18	16.2	54.0	49	6	AX952638
19	16.2	54.0	60	6	CQ536369

20	16.2	54.0	70	6	E15744
21	15.8	52.7	41	6	AR109135
22	15.8	52.7	41	6	AR200790
23	15.8	52.7	47	6	AR284458
24	15.4	51.3	43	6	AX484469
25	15.4	51.3	51	6	CQ007362
26	15.4	51.3	65	6	CQ560587
27	15.2	50.7	40	6	AX774088
28	15	50.0	41	6	AX515819
29	15	50.0	41	6	AX518414
30	15	50.0	50	6	AX952015
31	15	50.0	50	6	AX952045
32	15	50.0	50	6	AX952063
33	15	50.0	50	6	AX952609
34	15	50.0	50	6	AX952639
35	15	50.0	50	6	AX952657
36	15	50.0	60	6	CQ831872
37	14.8	49.3	35	6	E16238
38	14.8	49.3	35	6	E16283
39	14.8	49.3	35	6	AX128301
40	14.8	49.3	36	3	AF251753S5
41	14.8	49.3	43	6	AX484455
42	14.8	49.3	47	6	AR284544
43	14.8	49.3	59	6	AX684244
44	14.8	49.3	65	6	CQ531914
45	14.8	49.3	65	6	CQ531944

ALIGNMENTS

RESULT 1

BD237979

LOCUS

BD237979

DEFINITION

Formulations comprising antisense nucleotides to connexins.

ACCESSION

BD237979

VERSION

BD237979.1 GI:33047749

KEYWORDS

JP 2002535377-A/1.

SOURCE

synthetic construct

ORGANISM

artificial sequences.

REFERENCE

1 (bases 1 to 30)

AUTHORS

Becker,D.L. and Green,C.R.

TITLE

Formulations comprising antisense nucleotides to connexins

JOURNAL

Patent: JP 2002535377-A 1 22-OCT-2002;

UNIVERSITY COLLEGE LONDON

COMMENT

OS Artificial Sequence

PN JP 2002535377-A/1

PD 22-OCT-2002

PF 27-JAN-2000 JP 2000595711

PR 27-JAN-1999 NZ 333928, 07-OCT-1999 NZ 500190 PI

PC DAVID LAURENCE BECKER, COLIN RICHARD GREEN

PC A61K31/711,A61K9/06,A61K9/10,A61K47/16,A61K47/34,A61K47/46, PC

A61K48/00,

PC A61P17/02,A61P17/12,A61P17/16,A61P25/00,A61P29/00,A61P43/00,

PC A61P43/00//

PC C12N15/09,C12N15/00

CC Description of Artificial Sequence: Oligonucleotide FH Key

Location/Qualifiers

FT source

FT 1..30

Location/Qualifiers

1..30

/organism="synthetic construct"

/mol_type="genomic DNA"

/db_xref="taxon:32630"

FEATURES

source

ORIGIN

Query Match 100.0%; Score 30; DB 6; Length 30;

Best Local Similarity 100.0%; Pred.No. 0.014;

Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1 GTAATTGCGGCAAGAGAAATTGTTCTGTC 30

```

Db      1  GTAAATGCGGCAAGAGAAATGTTTCTGTC 30
|||||
RESULT 2
AX032823
LOCUS      30 bp      DNA      linear      PAT 21-SEP-2000
DEFINITION
Sequence 1 from Patent WO044409.
ACCESSION  AX032823
VERSION     AX032823.1  GI:10279797
KEYWORDS   synthetic construct
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1
AUTHORS    Becker, D.L. and Green, C.R.
TITLE      Formulations comprising antisense nucleotides to connexins
JOURNAL    Patent: WO 0044409-A 1 03-AUG-2000;
          BECKER DAVID LAURENCE (GB) ; UNIV LONDON (GB) ; GREEN COLIN RICHARD
          (NZ)
FEATURES   Location/Qualifiers
            source
              1..30
              /organism="synthetic construct"
              /mol_type="unassigned DNA"
              /db_xref="taxon:32630"
              /note="Oligonucleotide"
ORIGIN
Query Match      100.0%; Score 30; DB 6; Length 30;
Best Local Similarity 100.0%; Pred No. 0.014;
Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy      1  GTAAATGCGGCAAGAGAAATGTTTCTGTC 30
|||||
Db      1  GTAAATGCGGCAAGAGAAATGTTTCTGTC 30
|||||

RESULT 3
BD237980
LOCUS      30 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION
Formulations comprising antisense nucleotides to connexins.
ACCESSION  BD237980
VERSION     BD237980.1  GI:33047750
KEYWORDS   JP 2002535377-A/2.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1 (bases 1 to 30)
AUTHORS    Becker, D.L. and Green, C.R.
TITLE      Formulations comprising antisense nucleotides to connexins
JOURNAL    Patent: JP 2002535377-A 2 22-OCT-2002;
          UNIVERSITY COLLEGE LONDON
          OS Artificial Sequence
          PN JP 2002535377-A/2
          PD 22-OCT-2002
          PF 27-JAN-2000 JP 2000595711
          PR 27-JAN-1999 NZ 333928, 07-OCT-1999 NZ 500190 PI
          PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
          A61K48/00,
          PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
          PC A61P43/00//
          CC Description of Artificial Sequence: Oligonucleotide FH Key
          Location/Qualifiers
            FT source
              1..30
              /organism="Artificial Sequence".
FEATURES   source
            1..30
            /organism="synthetic construct"
            /mol_type="genomic DNA"
            /db_xref="taxon:32630"
ORIGIN

Query Match      89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39;
Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      1  GTAAATGCGGCAAGAGAAATGTTTCTGTC 30
|||||
Db      30  GTAAATGCGGCAAGAGAAATGTTTCTGTC 1
|||||

RESULT 5
BD237989/c
LOCUS      30 bp      DNA      linear      PAT 17-JUL-2003
DEFINITION
Formulations comprising antisense nucleotides to connexins.
ACCESSION  BD237989
VERSION     BD237989.1  GI:33047759
KEYWORDS   JP 2002535377-A/11.
SOURCE     synthetic construct
ORGANISM   artificial sequences.
REFERENCE  1 (bases 1 to 30)
AUTHORS    Becker, D.L. and Green, C.R.
TITLE      Formulations comprising antisense nucleotides to connexins
JOURNAL    Patent: JP 2002535377-A 11 22-OCT-2002;
          UNIVERSITY COLLEGE LONDON
          OS Artificial Sequence
          PN JP 2002535377-A/11
          COMMENT
            OS Artificial sequence
            PN JP 2002535377-A/11
  
```

PD 22-OCT-2002
PF 27-JAN-2000 JP 2000595711
PR 27-JAN-1999 NZ 333928, 07-OCT-1999 NZ 500190 PI
DAVID LAURENCE BECKER, COLIN RICHARD GREEN
PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
A61K48/00,
PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
PC A61P43/00//
PC C12N15/09, C12N15/00
CC Description of Artificial Sequence: Oligonucleotide FH Key
Location/Qualifiers
FT source 1.30
FT /organism="Artificial Sequence".
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="genomic DNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 0;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
Db 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 6
AX032824
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 2 from Patent WO0044409.
ACCESSION AX032824
VERSION AX032824.1 GI:10279798
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 004409-A 2 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 0;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
Db 1 GTAATTGGCGCAGGAGGAATTGTTCTGTC 30
RESULT 7
AX032829/c
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 7 from Patent WO0044409.
ACCESSION AX032829
VERSION AX032829.1 GI:10279803
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1

AUTHORS
Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 004409-A 7 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 2;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
Db 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 8
AX032833/c
LOCUS 30 bp DNA linear PAT 21-SEP-2000
DEFINITION Sequence 11 from Patent WO0044409.
ACCESSION AX032833
VERSION AX032833.1 GI:10279807
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: WO 004409-A 11 03-AUG-2000;
BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)
FEATURES
source
1.30
/organism="synthetic construct"
/mol_type="unassigned DNA"
/db_xref="taxon:32630"
/note="Oligonucleotide"
ORIGIN
Query Match 89.3%; Score 26.8; DB 6; Length 30;
Best Local Similarity 93.3%; Pred. No. 0.39; 2; Indels 0; Gaps 0;
Matches 28; Conservative 0; Mismatches 2;
QY 1 GTAATTGGCGCAAGAAGAAATTGTTCTGTC 30
Db 30 GTAATTGGCGCAGGAGGAATTGTTCTGTC 1
RESULT 9
BD237986
LOCUS 30 bp DNA linear PAT 17-JUL-2003
DEFINITION Formulations comprising antisense nucleotides to connexins.
ACCESSION BD237986
VERSION BD237986.1 GI:33047756
KEYWORDS JP 2002535377-A/8.
SOURCE synthetic construct
ORGANISM synthetic construct
artificial sequences.
REFERENCE 1 (bases 1 to 30)
AUTHORS Becker, D.L. and Green, C.R.
TITLE Formulations comprising antisense nucleotides to connexins
JOURNAL Patent: JP 2002535377-A 8 22-OCT-2002;
UNIVERSITY COLLEGE LONDON
COMMENT OS Artificial Sequence
PN JP 2002535377-A/8
PD 22-OCT-2002

PF 27-JAN-2000 JP 2000595711
 PR 27-JAN-1999 NZ 333928, 07-OCT-1999 NZ 500190 P1
 DAVID LAURENCE BECKER, COLIN RICHARD GREEN
 PC A61K31/711, A61K9/06, A61K9/10, A61K47/16, A61K47/34, A61K47/46, PC
 A61K48/00,
 PC A61P17/02, A61P17/12, A61P17/16, A61P25/00, A61P29/00, A61P43/00,
 PC A61P43/00//
 PC C12N15/09, C12N15/00
 CC Description of Artificial Sequence: Oligonucleotide FH Key
 Location/Qualifiers
 FT source 1..30
 FT /organism='Artificial Sequence'.
 Location/Qualifiers
 1..30
 /organism="synthetic construct"
 /mol_type="genomic DNA"
 /db_xref="taxon:32630"

ORIGIN
 Query Match 57.3%; Score 17.2; DB 6; Length 30;
 Best Local Similarity 73.3%; Pred. No. 8e+03; 8; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Cy 1 GTAATTCGGCAAGAGAAATGTTCTGTC 30
 Db 1 GTAGTTACGACAGGAGGAATGTTCTGTC 30

RESULT 10
 AX032830
 LOCUS 30 bp DNA linear PAT 21-SEP-2000
 DEFINITION Sequence 8 from Patent WO0044409.
 ACCESSION AX032830
 VERSION AX032830.1 GI:10279804
 KEYWORDS synthetic construct
 SOURCE synthetic construct
 ORGANISM artificial sequences.
 REFERENCE 1
 AUTHORS Becker, D.L. and Green, C.R.
 TITLE Formulations comprising antisense nucleotides to connexins
 JOURNAL Patent: WO 0044409-A 8 03-AUG-2000;
 BECKER DAVID LAURENCE (GB); UNIV LONDON (GB); GREEN COLIN RICHARD (NZ)

FEATURES
 source 1..30
 Location/Qualifiers
 /organism="synthetic construct"
 /mol_type="unassigned DNA"
 /db_xref="taxon:32630"
 /note="Oligonucleotide"

ORIGIN
 Query Match 57.3%; Score 17.2; DB 6; Length 30;
 Best Local Similarity 73.3%; Pred. No. 8e+03; 8; Indels 0; Gaps 0;
 Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Cy 1 GTAATTCGGCAAGAGAAATGTTCTGTC 30
 Db 1 GTAGTTACGACAGGAGGAATGTTCTGTC 30

RESULT 11
 AR411028/c
 LOCUS 43 bp DNA linear PAT 18-DEC-2003
 DEFINITION Sequence 17 from patent US 6635475.
 ACCESSION AR411028
 VERSION AR411028.1 GI:40162606
 KEYWORDS Unknown.
 SOURCE Unknown.
 ORGANISM Unclassified.
 REFERENCE 1 (bases 1 to 43)
 AUTHORS Helmann, J.D.

TITLE Bacillus subtilis extracytoplasmic function .sigma. factor
 JOURNAL Patent: US 6635475-A 17 21-OCT-2003;
 FEATURES Location/Qualifiers
 source 1..43
 /organism="unknown"
 /mol_type="genomic DNA"

ORIGIN
 Query Match 56.7%; Score 17; DB 6; Length 43;
 Best Local Similarity 80.0%; Pred. No. 1e+04; 5; Indels 0; Gaps 0;
 Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Cy 2 TAATTGGCGCAAGAGAAATGTTTC 26
 Db 31 TACGTGCAAGAAAGAGAAATGTTTC 7

RESULT 12
 BX547960
 LOCUS 65 bp DNA linear STS 02-JUL-2003
 DEFINITION Arabidopsis thaliana transposon insertion STS SM_3.39244, sequence tagged site.
 ACCESSION BX547960
 VERSION BX547960.1 GI:32440780
 KEYWORDS STS; STS, sequence tagged site.
 SOURCE Arabidopsis thaliana (thale cress)
 ORGANISM Arabidopsis thaliana
 Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
 Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
 rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
 REFERENCE 1
 AUTHORS Clarke, J.H., Bowles, B., Carter, J., Hart, D., McCullagh, B., Walsh, S.,
 Langham, S., LeGrys, C., Jones, J.D.G. and Bevan, M.
 JOURNAL Unpublished
 REFERENCE 2 (bases 1 to 65)
 AUTHORS Clarke, J.H.
 TITLE Direct Submission
 JOURNAL Submitted (02-JUL-2003) Clarke J.H., John Innes Centre, Colney Lane, Norwich, NR4 7UJ, UK
 COMMENT AT denotes an activation tag dissociation transposon within a single line. ET an enhancer trap dissociation transposon, GT a gene trap dissociation transposon, MT a mis-expression enhancer trap dissociation transposon, SM a defective suppressor mutator dissociation transposon. 3 denotes a sequence derived from the 3' end of the transposon. 5 denotes a sequence derived from the 5' end of the transposon. BBSRC GARNET, ATIS project
 On-line seed stock requests: http://nasc.nott.ac.uk/ NASC stock code: N125955.
 Location/Qualifiers
 source 1..65
 /organism="Arabidopsis thaliana"
 /mol_type="genomic DNA"
 /variety="Columbia-0 NASC stock code N1092"
 /db_xref="taxon:3702"
 /clone="AC022520"
 /note="Derived from superpool 17.29 NASC code N40772"

STS 1..65
 /standard_name="SM_3.39244"

ORIGIN
 Query Match 56.0%; Score 16.8; DB 11; Length 65;
 Best Local Similarity 90.0%; Pred. No. 1.3e+04; 2; Indels 0; Gaps 0;
 Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Cy 4 ATTGGCGCAAGAGAAATGTT 23
 Db 19 ATTGCTGCAGAGCAATGTT 38

RESULT 13
 AX952037/c
 LOCUS 50 bp RNA linear PAT 08-JAN-2004
 DEFINITION Sequence 94 from Patent WO03093504.

```

ACCESSION AX952037
VERSION AX952037.1 GI:40782419
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Vater,A., Jarosch,F., Wettich,A. and Klussmann,S.
TITLE Method for amplifying nucleic acids
JOURNAL Patent: WO 03093504-A 94 13-NOV-2003;
Noxxon Pharma AG (DE)
FEATURES
source 1..50
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 55.3%; Score 16.6; DB 6; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.5e+04;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 8 CGGCAAGAGAAATGTTTCTGTC 30
Db 36 CGTCAGACGAATCGTTTCTTTC 14

RESULT 14
AX952631/c
LOCUS AX952631 50 bp RNA linear PAT 08-JAN-2004
DEFINITION Sequence 186 from Patent WO03093472.
ACCESSION AX952631
VERSION AX952631.1 GI:40782971
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Vater,A., Maasch,C., Jarosch,F., Bell,M., Helmling,S.,
Schiglaeller,B., Moyroud,S., Stark,S., Klussmann,S., Ruppert,T.,
Schiene,K., Bahrenberg,G. and Gillen,C.
TITLE Cgrp binding nucleic acids
JOURNAL Patent: WO 03093472-A 186 13-NOV-2003;
Gruenthal GmbH (DE) ; Noxxon Pharma AG (DE)
FEATURES
source 1..50
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
/note="CGRP-binding nucleic acid"
ORIGIN
Query Match 55.3%; Score 16.6; DB 6; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.5e+04;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 8 CGGCAAGAGAAATGTTTCTGTC 30
Db 36 CGTCAGACGAATCGTTTCTTTC 14

RESULT 15
AX952011/c
LOCUS AX952011 49 bp RNA linear PAT 08-JAN-2004
DEFINITION Sequence 68 from Patent WO03093504.
ACCESSION AX952011
VERSION AX952011.1 GI:40782393
KEYWORDS
SOURCE synthetic construct
ORGANISM synthetic construct
REFERENCE 1
AUTHORS Vater,A., Jarosch,F., Wettich,A. and Klussmann,S.

```

```

TITLE Method for amplifying nucleic acids
JOURNAL Patent: WO 03093504-A 68 13-NOV-2003;
Noxxon Pharma AG (DE)
FEATURES
source 1..49
Location/Qualifiers
/organism="synthetic construct"
/mol_type="unassigned RNA"
/db_xref="taxon:32630"
ORIGIN
Query Match 54.0%; Score 16.2; DB 6; Length 49;
Best Local Similarity 72.4%; Pred. No. 2.3e+04;
Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAAATGTTTCTGTC 30
Db 42 TCATCGTCACAAGACGAATCGTTTCTTTC 14

Search completed: November 5, 2004, 16:35:12
Job time : 2550 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 13:14:14 ; Search time 343 Seconds
(without alignments)
459.133 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattgcgcgaagaagaattgtttctgtc 30

Scoring table: IDENTITY NUC

Gapop 10.0 , Gapext 1.0

Searched: 4134886 seqs, 2624710521 residues

Total number of hits satisfying chosen parameters: 4224226

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : N_Geneseq_23Sep04.*

- 1: Geneseq1980s.*
- 2: Geneseq1990s.*
- 3: Geneseq2000s.*
- 4: Geneseq2001as.*
- 5: Geneseq2001bs.*
- 6: Geneseq2002as.*
- 7: Geneseq2002bs.*
- 8: Geneseq2003as.*
- 9: Geneseq2003bs.*
- 10: Geneseq2003cs.*
- 11: Geneseq2003ds.*
- 12: Geneseq2004s.*

* Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	30	100.0	30	3	AAA71646 Connexin
2	26.8	89.3	30	3	AAA71647 Connexin
3	26.8	89.3	30	3	AAA71652 Connexin
4	17.2	57.3	30	3	AAA71653 Chickens c
5	17	56.7	43	10	Adf50888 Bacillus
6	16.6	55.3	50	11	Adm73609 CGRP-bind
7	16.6	55.3	50	11	Adm68129 Oligonuc
8	16.6	55.3	50	11	Adm68129 Oligonuc
9	16.2	54.0	49	11	Adm73616 CGRP-bind
10	16.2	54.0	49	11	Adm73583 CGRP-bind
11	16.2	54.0	49	11	Adm67858 Rat alpha
12	16.2	54.0	49	11	Adm68137 Oligonuc
13	16.2	54.0	49	11	Adm68170 Oligonuc
14	16.2	54.0	49	11	Adm68130 Oligonuc
15	16.2	54.0	49	11	Adm67825 Rat alpha
16	16.2	54.0	60	6	Abn35256 Human spl
17	16.2	54.0	70	2	Aav23259 Synthetic
18	15.8	52.7	27	3	Aaz87224 Pinctada
19	15.8	52.7	41	2	Aav50625 Brassica
20	15.8	52.7	41	6	Ab196067 Brassica
21	15.6	52.0	24	6	ABL41518 Primer #2

22	15.4	51.3	43	6	AB227822	Candida e
23	15.4	51.3	51	4	AAL32794	Human SNP
24	15.4	51.3	65	6	ABN57474	Mouse spl
25	15.2	50.7	40	10	ACC59609	S aureus
26	15.2	50.7	57	2	AAQ55412	Antifunga
27	15.2	50.7	73	9	AAL56857	Chimeric
28	15.2	50.7	75	2	AAX33550	Rice beta
29	15	50.0	50	11	ADM73587	CGRP-bind
30	15	50.0	50	11	ADM73635	CGRP-bind
31	15	50.0	50	11	ADM73617	CGRP-bind
32	15	50.0	50	11	ADM68138	Oligonuc
33	15	50.0	50	11	ADM68128	Oligonuc
34	15	50.0	50	11	ADM68128	Oligonuc
35	15	50.0	50	11	ADM67859	Rat alpha
36	15	50.0	50	11	ADM67877	Rat alpha
37	15	50.0	50	11	ADM67829	Rat alpha
38	15	50.0	50	11	ADM68139	Oligonuc
39	15	50.0	50	11	ADM68169	Oligonuc
40	15	50.0	60	12	ADQ76911	Escherich
41	14.8	49.3	29	3	AA93601	Human APC
42	14.8	49.3	34	2	AAX99849	PCR prime
43	14.8	49.3	35	2	AAV27021	Primer GT
44	14.8	49.3	35	2	AAV35868	PCR prime
45	14.8	49.3	35	4	AAS05357	Mouse alp

ALIGNMENTS

RESULT 1
AAA71646
ID AAA71646 standard; DNA; 30 BP.
XX
AC AAA71646;
XX
DT 15-DEC-2000 (first entry)
XX
DE Connexin 43 primer DNA #1.
XX
KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
KW vulnery; antiinflammatory; dermatology; site-specific downregulation;
KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
KW inflammation reduction; scar formation; epithelial basal cell division;
KW keratinization; skin rejuvenation; primer; ss.
XX
OS Unidentified.
XX
PN WO200044409-A1.
XX
PD 03-AUG-2000.
XX
PF 27-JAN-2000; 2000WO-GB000238.
XX
PR 27-JAN-1999; 99NZ-00333928.
PR 07-OCT-1999; 99NZ-00500190.
PA (UNLO) UNIV COLLEGE LONDON.
XX
PI Adm73609 CGRP-bind
XX
DR Adm68129 Oligonuc
XX
DR Adm67851 Rat alpha
XX
DR Adm73616 CGRP-bind
XX
DR Adm73583 CGRP-bind
XX
PT Adm67858 Rat alpha
XX
PT Adm68137 Oligonuc
XX
PT Adm68170 Oligonuc
XX
XX Adm68130 Oligonuc
XX
PS Adm7825 Rat alpha
XX
PS Abn35256 Human spl
XX
CC Aav23259 Synthetic
XX
CC Aaz87224 Pinctada
XX
CC Aav50625 Brassica
XX
CC Ab196067 Brassica
XX
CC ABL41518 Primer #2

Claim 9; Page 2; 64pp; English.
This invention describes a novel formulation (i) for use in therapeutic and/or cosmetic treatment, comprising at least one antisense polynucleotide (ii) to a connexin protein together with a carrier or vehicle. The products of the invention have neuroprotective, vulnerary, antiinflammatory and dermatological activity. (ii) is useful in a

CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result
 CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX
 SQ Sequence 30 BP; 8 A; 4 C; 8 G; 10 T; 0 U; 0 Other;
 Query Match 100.0%; Score 30; DB 3; Length 30;
 Best Local Similarity 100.0%; Pred. No. 0.0021;
 Matches 30; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 1 GTAATTGGCGCAAGAGAAATGTTTCTGTC 30
 Db 1 GTAATTGGCGCAAGAGAAATGTTTCTGTC 30
 RESULT 2
 AAA71647
 ID AAA71647 standard; DNA; 30 BP.
 XX
 AC AAA71647;
 XX
 DT 15-DEC-2000 (first entry)
 XX
 DE Connexin 43 primer DNA #2.
 XX
 KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
 KW vulnery; antiinflammatory; dermatology; site-specific downregulation;
 KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
 KW inflammation reduction; scar formation; epithelial basal cell division;
 KW keratinization; skin rejuvenation; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200044409-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-GB000238.
 XX
 PR 27-JAN-1999; 99NZ-00333928.
 PR 07-OCT-1999; 99NZ-00500190.
 XX
 PA (UNLO) UNIV COLLEGE LONDON.
 XX
 PI Becker DL, Green CR;
 XX
 DR WPI; 2000-491220/43.
 XX
 PT New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.
 XX
 PS Claim 9; Page 2; 64pp; English.
 XX
 CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnery,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result

CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result
 CC of a wound or physical trauma of the brain, spinal cord or optic nerve
 CC and for decreasing scar formation. (I) containing (II) directed to
 CC connexin 43 or 31.1 is administered to regulate epithelial basal cell
 CC division and growth or to regulate outer layer keratinization,
 CC respectively, for skin rejuvenation or thickening for cosmetic or
 CC therapeutic purposes (I) downregulates connexin expression in a highly
 CC desirable site-specific manner. This sequence represents a connexin-43
 CC directed oligonucleotide which is used in the method of the invention
 XX
 SQ Sequence 30 BP; 6 A; 4 C; 10 G; 10 T; 0 U; 0 Other;
 Query Match 89.3%; Score 26.8; DB 3; Length 30;
 Best Local Similarity 93.3%; Pred. No. 0.054; 2; Indels 0; Gaps 0;
 Matches 28; Conservative 0; Mismatches 0;
 QY 1 GTAATTGGCGCAAGAGAAATGTTTCTGTC 30
 Db 1 GTAATTGGCGCAGGAGAAATGTTTCTGTC 30
 RESULT 3
 AAA71652/c
 ID AAA71652 standard; DNA; 30 BP.
 XX
 AC AAA71652;
 XX
 DT 15-DEC-2000 (first entry)
 XX
 DE Connexin 43 primer DBIsense DNA.
 XX
 KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;
 KW vulnery; antiinflammatory; dermatology; site-specific downregulation;
 KW neuronal insult; brain; spinal cord; optic nerve; wound healing;
 KW inflammation reduction; scar formation; epithelial basal cell division;
 KW keratinization; skin rejuvenation; primer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200044409-A1.
 XX
 PD 03-AUG-2000.
 XX
 PF 27-JAN-2000; 2000WO-GB000238.
 XX
 PR 27-JAN-1999; 99NZ-00333928.
 PR 07-OCT-1999; 99NZ-00500190.
 XX
 PA (UNLO) UNIV COLLEGE LONDON.
 XX
 PI Becker DL, Green CR;
 XX
 DR WPI; 2000-491220/43.
 XX
 PT New formulation for therapeutic and/or cosmetic treatment of neuronal
 PT cell death, inflammation and scar formation, comprises antisense
 PT polynucleotide to connexin protein.
 XX
 PS Example 1; Page 17; 64pp; English.
 XX
 CC This invention describes a novel formulation (I) for use in therapeutic
 CC and/or cosmetic treatment, comprising at least one antisense
 CC polynucleotide (II) to a connexin protein together with a carrier or
 CC vehicle. The products of the invention have neuroprotective, vulnery,
 CC antiinflammatory and dermatological activity. (II) is useful in a
 CC formulation (I), which is administered to a site on or within a patient
 CC for the site-specific downregulation of connexin protein expression. (I)
 CC is therefore specifically useful for reducing neuronal cell death
 CC resulting from neuronal insult to a specific site in the brain, spinal
 CC cord or optic nerve of a patient, for promoting wound healing resulting
 CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve

CC and for decreasing scar formation. (I) containing (II) directed to

CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,

CC respectively, for skin rejuvenation or thickening for cosmetic or

CC therapeutic purposes (I) downregulates connexin expression in a highly

CC desirable site-specific manner. This sequence represents a connexin-43

CC directed oligonucleotide which is used in the method of the invention

CC

XX Sequence 30 BP; 10 A; 10 C; 4 G; 6 T; 0 U; 0 Other;

SQ

Query Match 89.3%; Score 26.8; DB 3; Length 30;

Best Local Similarity 93.3%; Pred. No. 0.054;

Matches 28; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1 GTAATTGGCGCAAGAGAAATTTCTGTC 30

Db 30 GTAATTGGCGCAGGAGAAATTTCTGTC 1

RESULT 4

AAA71653

ID AAA71653 standard; DNA; 30 BP.

XX

AC AAA71653;

XX

DT 15-DEC-2000 (first entry)

XX

DE Chicken connexin 43 primer DB1 DNA.

XX

KW Connexin; connexin 43; cosmetic treatment; therapy; neuroprotective;

KW vulnary; antiinflammatory; dermatology; site-specific downregulation;

KW neuronal insult; brain; spinal cord; optic nerve; wound healing;

KW inflammation reduction; scar formation; epithelial basal cell division;

KW keratinization; skin rejuvenation; primer; chicken; ss.

XX

OS Gallus sp.

XX

PN WC2000044409-A1.

XX

PD 03-AUG-2000.

XX

PF 27-JAN-2000; 2000WC-GB000238.

XX

PR 27-JAN-1999; 99NZ-00333928.

PR 07-OCT-1999; 99NZ-00500190.

XX

PA (UNLO) UNIV COLLEGE LONDON.

XX

PI Becker DL, Green CR;

XX

DR WPI; 2000-491220/43.

XX

XX New formulation for therapeutic and/or cosmetic treatment of neuronal

PT cell death, inflammation and scar formation, comprises anisense

PT polynucleotide to connexin protein.

XX

XX Example 1; Page 17; 64pp; English.

XX

XX This invention describes a novel formulation (I) for use in therapeutic

CC and/or cosmetic treatment, comprising at least one antisense

CC polynucleotide (II) to a connexin protein together with a carrier or

CC vehicle. The products of the invention have neuroprotective, vulnerary,

CC antiinflammatory and dermatological activity. (II) is useful in a

CC formulation (I), which is administered to a site on or within a patient

CC for the site-specific downregulation of connexin protein expression. (I)

CC is therefore specifically useful for reducing neuronal cell death

CC resulting from neuronal insult to a specific site in the brain, spinal

CC cord or optic nerve of a patient, for promoting wound healing resulting

CC from trauma, burns or surgery and for reducing inflammation as a result

CC of a wound or physical trauma of the brain, spinal cord or optic nerve

CC and for decreasing scar formation. (I) containing (II) directed to

CC connexin 43 or 31.1 is administered to regulate epithelial basal cell

CC division and growth or to regulate outer layer keratinization,

CC respectively, for skin rejuvenation or thickening for cosmetic or

CC therapeutic purposes (I) downregulates connexin expression in a highly

CC desirable site-specific manner. This sequence represents a connexin-43

CC directed oligonucleotide which is used in the method of the invention

CC

XX Sequence 30 BP; 7 A; 5 C; 9 G; 9 T; 0 U; 0 Other;

SQ

Query Match 57.3%; Score 17.2; DB 3; Length 30;

Best Local Similarity 73.3%; Pred. No. 9.1e+02;

Matches 22; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 1 GTAATTGGCGCAAGAGAAATTTCTGTC 30

Db 1 GTAATTACGACAGGAGAAATTTCTGTC 30

RESULT 5

ADF50888/c

ID ADF50888 standard; DNA; 43 BP.

XX

AC ADF50888;

XX

DT 12-FEB-2004 (first entry)

XX

DE Bacillus subtilis yfhl DNA oligo homologous to sigW.

XX

KW ss; ECF; sigma factor; extracytoplasmic function;

KW autoregulatory promoter; Px; sigW; Pw; detoxification; antimicrobial;

KW bacterial growth; replication; sigX.

XX

OS Bacillus subtilis.

XX

PN US6635475-B1.

XX

PD 21-OCT-2003.

XX

PF 28-JUL-2000; 2000US-00627746.

XX

PR 30-JUL-1999; 99US-0146466P.

XX

PA (CORR) CORNELL RES FOUND INC.

XX

PI Helmann JD;

XX

XX WPI; 2003-810568/76.

XX

PT New Bacillus subtilis sigW gene encoding an extracytoplasmic function

PT alpha factor, useful for screening assays to identify potential

PT antibacterial agents.

XX

PS Disclosure, SEQ ID NO 17; 18pp; English.

XX

XX This invention relates to novel Bacillus subtilis extracytoplasmic

CC function (ECF) sigma factors. These ECF sigma factors regulate their own

CC expression, accordingly the sigX operon is preceded by an autoregulatory

CC promoter named Px and likewise the sigW operon is autoregulated by the W-

CC dependent promoter Pw. A consensus based search approach was used to

CC identify further operons preceded by promoters similar in sequence to Pw

CC and hence recognised by SigW, such that SigW has been shown to control a

CC regulon of more than 30 genes including flitilin and epoxide hydrolase.

CC Specifically, SigW activates a large stationary phase regulon that

CC functions in detoxification and/ or the production of antimicrobial

CC compounds that can be used to modulate bacterial growth and replication.

CC This oligonucleotide sequence is the Bacillus subtilis yfhl DNA that is

CC homologous to sigW of the invention.

XX

SQ Sequence 43 BP; 14 A; 8 C; 8 G; 13 T; 0 U; 0 Other;

Query Match 56.7%; Score 17; DB 10; Length 43;

Best Local Similarity 80.0%; Pred. No. 1.2e+03;

Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

OY 2 TAATTGGCGCAAGAAATGTTTC 26
 DB 31 TACGTGCAGANAGAAATGTTTC 7
 RESULT 6
 ADM73609/c
 ID ADM73609 standard; RNA; 50 BP.
 XX
 AC ADM73609;
 DT 03-JUN-2004 (first entry)
 XX
 DE CGRP-binding ribo-oligonucleotide STAR-R02-15d-G12.
 KW antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypotension; hypertension;
 KW tachycardia; trigeminal afferent sensory neuron activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydipsia; ss.
 OS Synthetic.
 XX
 PN WO2003093472-A2.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004746.
 XX
 PR 06-MAY-2002; 2002DE-01020188.
 PR 04-NOV-2002; 2002DE-01051246.
 XX
 PA (CHEF) GRUENENTHAL GMBH.
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Maasch C, Jarosch F, Bell M, Helmling S, Bachofaeller B;
 PI Moyroud E, Stark S, Klussmann S, Ruppert T, Schiene K, Bahrenberg G;
 PI Gillen C;
 XX
 DR WPI; 2003-854484/79.
 XX
 PT New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.
 XX
 PS Claim 15; SEQ ID NO 196; 263pp; German.
 XX
 CC This invention describes a novel antagonist of CGRP (calcitonin gene-
 CC related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound
 CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 168 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (STM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neurotransmitters), vasodilation, hypo- or hyper-tension, tachycardia,
 CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC Generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting

CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.
 XX
 SQ Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
 Query Match 55.3%; Score 16.6; DB 11; Length 50;
 Best Local Similarity 82.6%; Pred. NO. 1.8e+03;
 Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 8 CGGCACGACGAATGTTCTGTC 30
 DB 36 CGTCAGACGATCGTTCTTC 14
 RESULT 7
 ADM68129/c
 ID ADM68129 standard; DNA; 50 BP.
 XX
 AC ADM68129;
 DT 03-JUN-2004 (first entry)
 XX
 DE Oligonucleotide STAR-R02-15d-G12.
 KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 OS Synthetic.
 XX
 PN WO2003093504-A1.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004747.
 XX
 PR 06-MAY-2002; 2002DE-01020191.
 XX
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX
 DR WPI; 2003-854487/79.
 XX
 PT Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 XX
 PS Example 12; Fig 35; 262pp; German.
 XX
 CC This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP, calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short

CC sequences.
XX Sequence 50 BP; 16 A; 9 C; 16 G; 9 T; 0 U; 0 Other;
SQ

Query Match 55.3%; Score 16.6; DB 11; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.8e+03;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 8 CGGCAAGAGAAATGTTTCTGTC 30
DB 36 CGTCAAGACGAATCGTTTCTTTC 14

RESULT 8
ADM67851/c
ID ADM67851 standard; RNA; 50 BP.
XX
AC ADM67851;
XX
DT 03-JUN-2004 (first entry)
XX
DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 94.
XX
KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
KW drug design; primer; ss.
XX
OS Rattus sp.
XX
DN WO2003093504-A1.
XX
PD 13-NOV-2003.
XX
XX 06-MAY-2003; 2003WO-EP004747.
XX
XX 06-MAY-2002; 2002DE-01020191.
XX
XX (NOXX-) NOXXON PHARMA AG.
XX
XX Vater A, Jarosch F, Wettich A, Klusmann S;
XX WPI; 2003-854487/79.
XX
XX Amplification of nucleic acid using two adapters, useful for selection
XX and preparation of aptamers, potential therapeutic agents, with all steps
XX done in one vessel.
XX
XX Example 12; SEQ ID NO 94; 262pp; German.
XX
XX This invention describes a novel method for amplifying nucleic acids. The
XX method comprises 1) preparing a target to be amplified, preferably RNA,
XX having defined 5' and 3' sequences, separated by an intermediate
XX sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
XX acid (especially one strand of RNA and the other DNA), where the 5'-end
XX of the DNA strand has an overhang at least partly complementary with the
XX 5'-end of the target, 3) preparing a second adapter (Ad2) of double
XX stranded nucleic acid, where the first strand has a 5'-phosphate residue
XX on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
XX least partly complementary with the 3'-end of the target, the second
XX strand also has a cleavage site which can generate a cleavage product
XX that includes the complementary 3'-end of the second strand, 4) the
XX adapters are ligated on the target, 5) reverse transcription is performed
XX and optionally the second strand is synthesised. The products of the
XX invention have antimigraine and analgesic activity. The method is
XX especially used for selection and preparation of nucleic acids including
XX L-nucleic acids, that bind to selected targets (aptamers), potentially
XX useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
XX gene-related peptide) or amylin or their receptors, suitable for
XX treatment of pain, migraine and other conditions, also as starting points
XX for rational drug design, in screening for therapeutic compounds and for
XX target validation. The method can be done in a single vessel, without
XX purification of process intermediates and it can be applied to short
XX sequences. ADM67759-ADM67903 represent oligonucleotides capable of

CC binding to rat CGRP which are used to illustrate the method of the
CC invention.
XX
XX Sequence 50 BP; 16 A; 9 C; 16 G; 0 T; 9 U; 0 Other;
SQ

Query Match 55.3%; Score 16.6; DB 11; Length 50;
Best Local Similarity 82.6%; Pred. No. 1.8e+03;
Matches 19; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
OY 8 CGGCAAGAGAAATGTTTCTGTC 30
DB 36 CGTCAAGACGAATCGTTTCTTTC 14

RESULT 9
ADM73616/c
ID ADM73616 standard; RNA; 49 BP.
XX
AC ADM73616;
XX
DT 03-JUN-2004 (first entry)
XX
DE CGRP-binding ribo-oligonucleotide STAR-R02-15xx-B10.
XX
KW antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
KW neurogenic inflammation; vasodilation; hypotension; hypertension;
KW tachycardia; trigeminal afferent sensory neuron activation;
KW central nociceptive neuron; inflammatory pain; diabetes;
KW gastric emptying; diabetic gastroparesis; polydipsia; ss.
XX
OS Synthetic.
XX
XX WO2003093472-A2.
XX
XX 13-NOV-2003.
XX
XX 06-MAY-2003; 2003WO-EP004746.
XX
XX 06-MAY-2002; 2002DE-01020188.
XX
XX 04-NOV-2002; 2002DE-01051246.
XX
XX (CHEF) GRUENTHAL GMBH.
XX
XX (NOXX-) NOXXON PHARMA AG.
XX
XX Vater A, Maasch C, Jarosch F, Bell M, Helming S, Eschgfeller B;
XX Movroud E, Stark S, Klusmann S, Ruppert T, Schiene K, Bahrenberg G;
XX Gillen C;
XX
XX WPI; 2003-854484/79.
XX
XX New antagonists of calcitonin gene-related peptide or amylin, useful for
XX treating or preventing e.g. migraine or inflammation, are specific
XX binding nucleic acids.
XX
XX Claim 15; SEQ ID NO 193; 263pp; German.
XX
XX This invention describes a novel antagonist of CGRP (calcitonin gene-
XX related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
XX fluoro substituted on pyrimidine nucleotides) was incubated with
XX biotinylated CGRP for 3 hours at 37degC, then the incubation mixture
XX applied to a matrix coated with streptavidin for 10 minutes at 37degC.
XX The matrix was separated, washed with selection buffer and bound RNA
XX recovered by elution with an excess of non-biotinylated CGRP. The bound
XX RNA released this way was amplified and the selection procedure repeated
XX for a total of 18 rounds, after which reverse transcription produced 192
XX clones. One sequence was present in 168 of these clones. This sequence
XX had a Kd of 10 nM and was used as starting sequence for preparation of
XX optimised and truncated RNA aptamers or spiegelmers (RM). Antagonists of
XX CGRP, amylin and amyloid polypeptides are useful for treating and/or
XX preventing: migraine, cluster headache, lack of appetite, nausea,
XX vomiting, neurogenic inflammation (especially where mediated by other
XX neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,

CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting
 CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.

XX SQ Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGCGCAAGAAGAAATGTTCTGTC 30

Db 42 TCATCGTCGCTAGCAAGATCGTTCTTTC 14

RESULT 10

ADM73583/c

ID ADM73583 standard; RNA; 49 BP.

XX AC ADM73583;

XX DT 03-JUN-2004 (first entry)

XX CGRP-binding ribo-oligonucleotide STAR-R02-12MW-E3.

XX antagonist; CGRP; calcitonin gene-related peptide; amylin; amyloid;
 KW spiegelmer; migraine; cluster headache; appetite loss; nausea; vomiting;
 KW neurogenic inflammation; vasodilation; hypotension; hypertension;
 KW tachycardia; trigeminal afferent sensory neuron activation;
 KW central nociceptive neuron; inflammatory pain; diabetes;
 KW gastric emptying; diabetic gastroparesis; polydipsia; ss.

XX Synthetic.

XX WO2003093472-A2.

XX PD 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004746.

XX 06-MAY-2002; 2002DE-01020188.

XX 04-NOV-2002; 2002DE-01051246.

XX (CHEF) GRUENTHAL GMBH.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Maasch C, Jarosch F, Bell M, Helmling S, Eschgfäller B;
 PI Meyrout E, Stark S, Klusmann S, Ruppert T, Schiene K, Bahrenberg G;
 PI Gillen C;

XX WPI; 2003-854484/79.

XX New antagonists of calcitonin gene-related peptide or amylin, useful for
 PT treating or preventing e.g. migraine or inflammation, are specific
 PT binding nucleic acids.

XX Claim 15; SEQ ID NO 160; 263pp; German.

XX This invention describes a novel antagonist of CGRP (calcitonin gene-
 CC related peptide), amylin or an amyloid polypeptide. A library of RNA (2'-
 CC fluoro substituted on pyrimidine nucleotides) was incubated with
 CC biotinylated CGRP, for 3 hours at 37degC, then the incubation mixture
 CC applied to a matrix coated with streptavidin for 10 minutes at 37degC.
 CC The matrix was separated, washed with selection buffer and bound RNA
 CC recovered by elution with an excess of non-biotinylated CGRP. The bound

CC RNA released this way was amplified and the selection procedure repeated
 CC for a total of 18 rounds, after which reverse transcription produced 192
 CC clones. One sequence was present in 166 of these clones. This sequence
 CC had a Kd of 10 nM and was used as starting sequence for preparation of
 CC optimised and truncated RNA aptamers or spiegelmers (RTM). Antagonists of
 CC CGRP, amylin and amyloid polypeptides are useful for treating and/or
 CC preventing: migraine, cluster headache, lack of appetite, nausea,
 CC vomiting, neurogenic inflammation (especially where mediated by other
 CC neuropeptides), vasodilation, hypo- or hyper-tension, tachycardia,
 CC diseases that are associated with activation of trigeminal afferent
 CC sensory neurons and central nociceptive neurons (especially of the higher
 CC pain centres and including chronic inflammatory pain) and/or pain
 CC generally (chronic, acute, inflammatory, visceral or neuropathic), where
 CC CGRP is the target and hypertension, diabetes, disorders of gastric
 CC emptying, diabetic gastroparesis and polydipsia, where amylin or amyloid
 CC peptides are the target. Antagonists that are nucleic acids are also
 CC useful for detecting CGRP, amylin and amyloid polypeptides or plaques, to
 CC screen for other CGRP and amylin antagonists or agonists, as starting
 CC materials for rational drug design, for target validation and for
 CC studying CGRP or amylin function.

XX SQ Sequence 49 BP; 15 A; 8 C; 16 G; 0 T; 10 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGCGCAAGAAGAAATGTTCTGTC 30

Db 42 TCATCGTCACAGCAAGATCGTTCTTTC 14

RESULT 11

ADM67858/c

ID ADM67858 standard; RNA; 49 BP.

XX AC ADM67858;

XX DT 03-JUN-2004 (first entry)

XX Rat alpha-D-CGRP binding oligonucleotide SEQ ID 101.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Rattus sp.

XX WO2003093504-A1.

XX PD 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; SEQ ID NO 101; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence. 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences. ADM67759-ADM67903 represent oligoribonucleotides capable of
 CC binding to rat CGRP which are used to illustrate the method of the
 CC invention.

XX
 SQ Sequence 49 BP; 16 A; 9 C; 16 G; 0 T; 8 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 2; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATTTCTGTC 30
 |||||
 Db 42 TCATCGTCTAGACGAATCGTTCTTTC 14

RESULT 12
 ADM68137/c
 ID ADM68137 standard; DNA; 49 BP.
 XX
 AC ADM68137;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Oligonucleotide STAR-R02-12NM-E3.
 XX
 KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX
 OS Synthetic.
 XX
 FN WO2003093504-A1.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004747.
 XX
 PR 06-MAY-2002; 2002DE-01020191.
 XX
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX
 DR WPI; 2003-854487/79.
 XX
 PT Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 XX
 PS Example 12; Fig 36; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

XX
 SQ Sequence 49 BP; 15 A; 8 C; 16 G; 10 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGCGGCAAGAGAAATTTCTGTC 30
 |||||
 Db 42 TCATCGTCTAGACGAATCGTTCTTTC 14

RESULT 13
 ADM68170/c
 ID ADM68170 standard; DNA; 49 BP.
 XX
 AC ADM68170;
 XX
 DT 03-JUN-2004 (first entry)
 XX
 DE Oligonucleotide STAR-R02-15xx-B10.
 XX
 KW nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.
 XX
 OS Synthetic.
 XX
 FN WO2003093504-A1.
 XX
 PD 13-NOV-2003.
 XX
 PF 06-MAY-2003; 2003WO-EP004747.
 XX
 PR 06-MAY-2002; 2002DE-01020191.
 XX
 PA (NOXX-) NOXXON PHARMA AG.
 XX
 PI Vater A, Jarosch F, Wettich A, Klussmann S;
 XX
 DR WPI; 2003-854487/79.
 XX
 PT Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.
 XX
 PS Example 12; Fig 37; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end

CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

XX
 XX
 SQ Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;
 Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAAGATTGTTCTGTC 30
 DB 42 TCATCGTCGTAGACGAATCGTTCTTC 14

RESULT 14

ADM68130/c
 ID ADM68130 standard; DNA; 49 BP.

XX
 AC ADM68130;

DT 03-JUN-2004 (first entry)

DE Oligonucleotide STAR-R02-15d-E1.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Synthetic.

XX WO2003093504-A1.

XX 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; Fig 35; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the

CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double
 CC stranded nucleic acid, where the first strand has a 5'-phosphate residue
 CC on (deoxy)ribose and the second strand (DNA) has a 3'-end that is at
 CC least partly complementary with the 3'-end of the target, the second
 CC strand also has a cleavage site which can generate a cleavage product
 CC that includes the complementary 3'-end of the second strand, 4) the
 CC adapters are ligated on the target, 5) reverse transcription is performed
 CC and optionally the second strand is synthesised. The products of the
 CC invention have antimigraine and analgesic activity. The method is
 CC especially used for selection and preparation of nucleic acids including
 CC L-nucleic acids, that bind to selected targets (aptamers), potentially
 CC useful as therapeutic agents, e.g. as antagonists of CGRP (calcitonin
 CC gene-related peptide) or amylin or their receptors, suitable for
 CC treatment of pain, migraine and other conditions, also as starting points
 CC for rational drug design, in screening for therapeutic compounds and for
 CC target validation. The method can be done in a single vessel, without
 CC purification of process intermediates and it can be applied to short
 CC sequences.

XX Sequence 49 BP; 16 A; 9 C; 16 G; 8 T; 0 U; 0 Other;

Query Match 54.0%; Score 16.2; DB 11; Length 49;

Best Local Similarity 72.4%; Pred. No. 2.7e+03;
 Matches 21; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAAGATTGTTCTGTC 30
 DB 42 TCATCGTCGTAGACGAATCGTTCTTC 14

RESULT 15

ADM67825/c

ID ADM67825 standard; RNA; 49 BP.

XX
 AC ADM67825;

DT 03-JUN-2004 (first entry)

DE Rat alpha-D-CGRP binding oligonucleotide SEQ ID 68.

XX nucleic acid amplification; antimigraine; analgesic; L-nucleic acid;
 KW CGRP antagonist; calcitonin gene-related peptide; amylin; pain;
 KW drug design; primer; ss.

XX Rattus sp.

XX WO2003093504-A1.

XX 13-NOV-2003.

XX 06-MAY-2003; 2003WO-EP004747.

XX 06-MAY-2002; 2002DE-01020191.

XX (NOXX-) NOXXON PHARMA AG.

XX Vater A, Jarosch F, Wettich A, Klusmann S;

XX WPI; 2003-854487/79.

XX Amplification of nucleic acid using two adapters, useful for selection
 PT and preparation of aptamers, potential therapeutic agents, with all steps
 PT done in one vessel.

XX Example 12; SEQ ID NO 68; 262pp; German.

XX This invention describes a novel method for amplifying nucleic acids. The
 CC method comprises 1) preparing a target to be amplified, preferably RNA,
 CC having defined 5' and 3' sequences, separated by an intermediate
 CC sequence, 2) preparing a first adapter (Ad1) of double-stranded nucleic
 CC acid (especially one strand of RNA and the other DNA), where the 5'-end
 CC of the DNA strand has an overhang at least partly complementary with the
 CC 5'-end of the target, 3) preparing a second adapter (Ad2) of double

GenCore version 5.1.6
Copyright (c) 1993 - 2004 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:29:37 ; Search time 71 Seconds
(without alignments)
300.333 Million cell updates/sec

Title: US-09-890-363-1
Perfect score: 30
Sequence: 1 gtaattgcgcgaagaattgtttctgtc 30

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 1.0

Searched: 824507 seqs, 355394441 residues

Total number of hits satisfying chosen parameters: 983458

Minimum DB seq length: 0
Maximum DB seq length: 75

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 45 summaries

Database : Issued Patents.NA.*
1: /cgn2_6/ptodata/1/ina/5A_COMB.seq.*
2: /cgn2_6/ptodata/1/ina/5B_COMB.seq.*
3: /cgn2_6/ptodata/1/ina/6A_COMB.seq.*
4: /cgn2_6/ptodata/1/ina/6B_COMB.seq.*
5: /cgn2_6/ptodata/1/ina/PTUS_COMB.seq.*
6: /cgn2_6/ptodata/1/ina/backfiles1.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
C 1	17	56.7	43	4	US-09-627-746-17
2	15.8	52.7	41	3	US-08-813-507-94
3	15.8	52.7	41	3	US-09-464-453-94
4	15.8	52.7	47	4	US-09-671-317-510
5	15.2	50.7	75	3	US-09-105-390-25
6	14.8	49.3	47	4	US-09-671-317-596
7	14.8	49.3	73	1	US-08-434-001-42
8	14.8	49.3	73	1	US-08-433-585-42
9	14.8	49.3	73	1	US-08-434-425-42
10	14.8	49.3	73	2	US-08-437-667-42
11	14.8	49.3	73	3	US-08-906-955-42
12	14.8	49.3	73	3	US-08-945-909-42
13	14.8	49.3	73	3	US-09-396-002A-42
14	14.8	49.3	73	3	US-10-077-319-42
15	14.8	49.3	73	5	PT-US96-06060-42
16	14.6	48.7	40	1	US-07-741-940-14
17	14.6	48.7	40	1	US-08-289-548A-14
18	14.6	48.7	40	1	US-08-452-654-14
19	14.6	48.7	40	1	US-08-452-655B-14
20	14.6	48.7	40	3	US-08-450-582-14
21	14.6	48.7	40	4	US-08-449-731-14
22	14.4	48.0	57	4	US-09-270-767-29842
23	14.4	48.0	61	3	US-09-275-850-56
24	14.2	47.3	27	3	US-09-257-584-13
25	14	46.7	24	3	US-09-186-170-15
26	14	46.7	24	4	US-09-562-868-15
27	14	46.7	24	4	US-10-116-288-15

C 28	14	46.7	27	3	US-09-186-170-16	Sequence 16, Appl
C 29	14	46.7	27	4	US-09-562-868-16	Sequence 16, Appl
C 30	14	46.7	27	4	US-10-116-288-16	Sequence 16, Appl
C 31	14	46.7	30	3	US-09-186-170-17	Sequence 17, Appl
C 32	14	46.7	30	4	US-09-562-868-17	Sequence 17, Appl
C 33	14	46.7	30	4	US-10-116-288-17	Sequence 17, Appl
C 34	14	46.7	33	3	US-09-186-170-14	Sequence 14, Appl
C 35	14	46.7	33	3	US-09-186-170-18	Sequence 14, Appl
C 36	14	46.7	33	4	US-09-562-868-14	Sequence 14, Appl
C 37	14	46.7	33	4	US-09-562-868-14	Sequence 14, Appl
C 38	14	46.7	33	4	US-10-116-288-14	Sequence 14, Appl
C 39	14	46.7	33	4	US-10-116-288-18	Sequence 18, Appl
C 40	14	46.7	36	3	US-09-186-170-10	Sequence 10, Appl
C 41	14	46.7	36	4	US-09-562-868-10	Sequence 10, Appl
C 42	14	46.7	36	4	US-10-116-288-10	Sequence 10, Appl
C 43	14	46.7	47	4	US-09-380-190A-32	Sequence 32, Appl
C 44	13.8	46.0	20	4	US-09-198-452A-3644	Sequence 3644, Ap
C 45	13.8	46.0	23	4	US-09-502-240-13	Sequence 13, Appl

ALIGNMENTS

RESULT 1

US-09-627-746-17/c
; Sequence 17, Application US/09627746
; Patent No. 6635475
; GENERAL INFORMATION:
; APPLICANT: Helmann, John
; TITLE OF INVENTION: Bacillus subtilis Extracytoplasmic Function Sigma Factor
; FILE REFERENCE: 10845-125
; CURRENT APPLICATION NUMBER: US/09/627,746
; CURRENT FILING DATE: 2000-07-28
; PRIOR APPLICATION NUMBER: US 60/146,466
; PRIOR FILING DATE: 1999-07-30
; NUMBER OF SEQ ID NOS: 21
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 17
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Bacillus subtilis
US-09-627-746-17

Query Match 56.7%; Score 17; DB 4; Length 43;
Best Local Similarity 80.0%; Pred. No. 97;
Matches 20; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAAGATTGTTTC 26

Db 31 TACGTGCAGAAAGAAATGTTTC 7

RESULT 2

US-08-813-507-94
; Sequence 94, Application US/08813507
; Patent No. 6114116
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; APPLICANT: Landry, Benoit S.
; APPLICANT: Sapolsky, Ronald J.
; TITLE OF INVENTION: Brassica Polymorphisms
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS

```

; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/813,507
; FILING DATE: 07-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/032,069
; FILING DATE: 02-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX:
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-813-507-94
;
; Query Match 52.7%; Score 15.8; DB 3; Length 41;
; Best Local Similarity 74.1%; Pred. No. 3.4e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 4 ATTGGCGCAAGAAGATTGTTTCTGTC 30
; DB 12 ATTGGGCTTGATGGATTGTTTCTATC 38
;
; RESULT 3
; US-09-464-453-94
; Sequence 94, Application US/09464453
; Patent No. 6358686
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; Sapolsky, Ronald J.
; TITLE OF INVENTION: Brassica Polymorphisms
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/464,453
; FILING DATE: 14-Dec-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/813,507
; FILING DATE: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-464-453-94
;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 94:
;
; US-09-464-453-94
;
; Query Match 52.7%; Score 15.8; DB 3; Length 41;
; Best Local Similarity 74.1%; Pred. No. 3.4e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 4 ATTGGCGCAAGAAGATTGTTTCTGTC 30
; DB 12 ATTGGGCTTGATGGATTGTTTCTATC 38
;
; RESULT 4
; US-09-671-317-510/c
; Sequence 510, Application US/09671317
; Patent No. 6528260
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Cohen, Annick
; TITLE OF INVENTION: BIALLELIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
; FILE REFERENCE: 62.US3.CIP
; CURRENT APPLICATION NUMBER: US/09/671,317
; CURRENT FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 09/536,178
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT/IB00/00403
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 60/126,269
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 60/131,961
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 977
; SOFTWARE: Patent.pm
; SEQ ID NO 510
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 12-456-269 : polymorphic base A or G
; US-09-671-317-510
;
; Query Match 52.7%; Score 15.8; DB 4; Length 47;
; Best Local Similarity 74.1%; Pred. No. 3.5e+02;
; Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
;
; QY 3 AATTCCGCGCAAGAAGATTGTTTCTGT 29
; DB 30 AATTCCGCGTAGAGAGATTCTGCTCT 4
;
; RESULT 5
; US-09-105-390-25/c
; Sequence 25, Application US/09105390
; Patent No. 6288303
; GENERAL INFORMATION:
; APPLICANT: Rodriguez, Raymond
; TITLE OF INVENTION: Rice Beta-Glucanase Enzymes
; TITLE OF INVENTION: and Genes
; NUMBER OF SEQUENCES: 66
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306

```

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/105,390
FILING DATE: Filed herewith
CLASSIFICATION:
PRIOR APPLICATION DATA: 60/050,675
APPLICATION NUMBER:
FILING DATE: 25-JUN-97
ATTORNEY/AGENT INFORMATION:
NAME: Petithory, Joanne R.
REGISTRATION NUMBER: P42,995
REFERENCE/DOCKET NUMBER: 2000-0455.30
TELECOMMUNICATION INFORMATION:
TELEPHONE: 650-324-0880
TELEFAX: 650-324-0960
TELEX:
INFORMATION FOR SEQ ID NO: 25:
SEQUENCE CHARACTERISTICS:
LENGTH: 75 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: Coding Sequence
LOCATION: 1...75
OTHER INFORMATION:
US-09-105-390-25
Query Match 50.7%; Score 15.2; DB 3; Length 75;
Best Local Similarity 71.4%; Pred. No. 7.2e+02;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
Qy 1 GTATTCCGGCAGAGAAATGTTCTG 28
Db 59 GGAATGCTGCAAGGAGCAATGCTACTG 32
RESULT 6
US-09-671-317-596
Sequence 596; Application US/09671317
Patent No. 6528260
GENERAL INFORMATION:
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
APPLICANT: Bougueleret, Lydie
APPLICANT: Cohen, Amick
TITLE OF INVENTION: BIALLIC MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
FILE REFERENCE: 62.US3.CIP
CURRENT APPLICATION NUMBER: US/09/671,317
CURRENT FILING DATE: 2000-09-27
PRIOR APPLICATION NUMBER: US 09/536,178
PRIOR FILING DATE: 2000-03-23
PRIOR APPLICATION NUMBER: PCT/IB00/00403
PRIOR FILING DATE: 2000-03-24
PRIOR APPLICATION NUMBER: US 60/126,269
PRIOR FILING DATE: 1999-03-25
PRIOR APPLICATION NUMBER: US 60/131,961
PRIOR FILING DATE: 1999-04-30
NUMBER OF SEQ ID NOS: 977
SOFTWARE: Patent.pm
SEQ ID NO 596
LENGTH: 47
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: allele
LOCATION: 24
OTHER INFORMATION: 2-11-284 : polymorphic base A or G
US-09-671-317-596

Query Match 49.3%; Score 14.8; DB 4; Length 47;
Best Local Similarity 80.0%; Pred. No. 9.9e+02;
Matches 16; Conservative 1; Mismatches 3; Indels 0; Gaps 0;
Qy 11 CAAGAAGAAATGTTTCTGTC 30
Db 20 CAAGRAGATTGTGCTATC 39
RESULT 7
US-08-434-001-42/c
Sequence 42; Application US/08434001
Patent No. 5712375
GENERAL INFORMATION:
APPLICANT: JENSEN, KIRK
APPLICANT: CHEN, HANG
APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
NUMBER OF SEQUENCES: 235
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 8400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/434,001
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-434-001-42
Query Match 49.3%; Score 14.8; DB 1; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
Qy 3 AATTGGCGCAGAGAAATGTTCTG 28
Db 55 AATAGCAGCAAGAAATAGGTTTCG 30

REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30C-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-945-909-42

Query Match 49.3%; Score 14.8; DB 3; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGAAATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 13
US-09-396-002A-42/c
; Sequence 42, Application US/09396002A
; Patent No. 6376474
; GENERAL INFORMATION:
; APPLICANT: HEILIG, JOSEPH S.
; GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; EXPONENTIAL ENRICHMENT: TISSUE SELEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 1745 Shea Center Drive, Suite 330
; CITY: Highlands Ranch
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80129
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/396,002A
; FILING DATE: 14-Sep-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; APPLICATION NUMBER: 08/434,001
; FILING DATE: 05-MAY-1995
; APPLICATION NUMBER: 08/906,955
; FILING DATE: 05-AUGUST-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30-5/D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 268-0066
; TELEFAX: (303) 268-0065
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-09-396-002A-42

Query Match 49.3%; Score 14.8; DB 3; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;

Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 AATTGGCGCAAGAAGAAATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 14
US-10-077-319-42/c
; Sequence 42, Application US/10077319
; Patent No. 6613526
; GENERAL INFORMATION:
; APPLICANT: HEILIG, JOSEPH S.
; GOLD, LARRY
; TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
; EXPONENTIAL ENRICHMENT: TISSUE SELEX
; NUMBER OF SEQUENCES: 240
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Swanson & Bratschun, L.L.C.
; STREET: 1745 Shea Center Drive, Suite 330
; CITY: Highlands Ranch
; STATE: Colorado
; COUNTRY: USA
; ZIP: 80129
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
; COMPUTER: IBM pc compatible
; OPERATING SYSTEM: MS-DOS
; SOFTWARE: WordPerfect 8.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/077,319
; FILING DATE: 14-Feb-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 09/396,002
; FILING DATE: 14-Sep-1999
; APPLICATION NUMBER: 07/714,131
; FILING DATE: 10-JUNE-1991
; APPLICATION NUMBER: 08/434,001
; FILING DATE: 05-MAY-1995
; APPLICATION NUMBER: 08/906,955
; FILING DATE: 05-AUGUST-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Barry J. Swanson
; REGISTRATION NUMBER: 33,215
; REFERENCE/DOCKET NUMBER: NEX30-5/D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (303) 268-0066
; TELEFAX: (303) 268-0065
; INFORMATION FOR SEQ ID NO: 42:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 73 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 42:
US-10-077-319-42

Query Match 49.3%; Score 14.8; DB 4; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGGCGCAAGAAGAAATTGTTCTG 28
DB 55 AATAGCAGCAAGAAATAGGTTTCGG 30

RESULT 15
PCT-US96-06060-42/c
; Sequence 42, Application PC/TUS9606060
; GENERAL INFORMATION:
; APPLICANT: JENSEN, KIRK
; APPLICANT: CHEN, HANG

APPLICANT: MORRIS, KEVIN
APPLICANT: STEPHENS, ANDREW
APPLICANT: GOLD, LARRY
TITLE OF INVENTION: SYSTEMATIC EVOLUTION OF LIGANDS BY
TITLE OF INVENTION: EXPONENTIAL ENRICHMENT: TISSUE
TITLE OF INVENTION: SELEX
NUMBER OF SEQUENCES: 240
CORRESPONDENCE ADDRESS:
ADDRESSEE: Swanson & Bratschun, L.L.C.
STREET: 9400 E. Prentice Avenue, Suite 200
CITY: Englewood
STATE: Colorado
COUNTRY: USA
ZIP: 80111
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 diskette, 1.44 MB
COMPUTER: IBM pc compatible
OPERATING SYSTEM: MS-DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/06060
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/714,131
FILING DATE: 10-JUNE-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/536,428
FILING DATE: 11-JUNE-1990
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/964,624
FILING DATE: 21-OCTOBER-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,425
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/437,667
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/434,001
FILING DATE: 05-MAY-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/433,585
FILING DATE: 05-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Barry J. Swanson
REGISTRATION NUMBER: 33,215
REFERENCE/DOCKET NUMBER: NEX30/PCT
TELEPHONE: (303) 793-3333
TELEFAX: (303) 793-3433
INFORMATION FOR SEQ ID NO: 42:
SEQUENCE CHARACTERISTICS:
LENGTH: 73 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
PCT-US96-06060-42

Query Match 49.3%; Score 14.8; DB 5; Length 73;
Best Local Similarity 73.1%; Pred. No. 1.1e+03;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;
QY 3 AATTGGCGCAAGAGAAATTGTTCTG 28
Db 55 AATAGCAGCAAGAAATAGGTTTCGG 30

Search completed: November 5, 2004, 17:15:09
Job time : 73 secs

RESULT 2
US-10-043-573-94
; Sequence 94, Application US/10043573
; Publication No. US2003002025A1
; GENERAL INFORMATION:
; APPLICANT: Lemieux, Bertrand
; Sapolsky, Ronald J.
; Landry, Benoit S.
; TITLE OF INVENTION: Brassica Polymorphisms
; NUMBER OF SEQUENCES: 173
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/10/043,573
; FILING DATE: 09-Jan-2002
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/813,507
; FILING DATE: 07-MAR-1997
; APPLICATION NUMBER: US 60/032,069
; FILING DATE: 02-DEC-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Liebeschuetz, Joe
; REGISTRATION NUMBER: 37,505
; REFERENCE/DOCKET NUMBER: 018547-030100US
; TELEPHONE: 415 576-0200
; TELEFAX: 415 576-0200
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 94:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 41 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 94:
US-10-043-573-94

Query Match 52.7%; Score 15.8; DB 14; Length 41;
Best Local Similarity 74.1%; Pred. No. 4e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 4 ATTGCGGCAAGAAATTTCTGTC 30
|||||
DB 12 ATTGGGTCTTGATGATTTCTATC 38

RESULT 3
US-10-294-934-510/c
; Sequence 510, Application US/10294934
; Publication No. US20040038231A1
; GENERAL INFORMATION:
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; APPLICANT: Bougueleret, Lydie
; APPLICANT: Cohen, Annick
; TITLE OF INVENTION: BIOMOLECULAR MARKERS RELATED TO GENES INVOLVED IN DRUG METABOLISM
; FILE REFERENCE: 62.USA.DIV
; CURRENT APPLICATION NUMBER: US/10/294,934
; CURRENT FILING DATE: 2000-09-27
; PRIOR APPLICATION NUMBER: US 09/671,317
; PRIOR FILING DATE: 2000-09-27

; PRIOR APPLICATION NUMBER: US 09/536,178
; PRIOR FILING DATE: 2000-03-23
; PRIOR APPLICATION NUMBER: PCT/IB00/00403
; PRIOR FILING DATE: 2000-03-24
; PRIOR APPLICATION NUMBER: US 60/126,269
; PRIOR FILING DATE: 1999-03-25
; PRIOR APPLICATION NUMBER: US 60/131,961
; PRIOR FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 977
; SOFTWARE: Patent.pm
; SEQ ID NO 510
; LENGTH: 47
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: allele
; LOCATION: 24
; OTHER INFORMATION: 12-456-269 : polymorphic base A or G
US-10-294-934-510

Query Match 52.7%; Score 15.8; DB 16; Length 47;
Best Local Similarity 74.1%; Pred. No. 4.1e+03;
Matches 20; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGCGGCAAGAAATTTCTGT 29
|||||
DB 30 AATTCCYCTAGAAATTTCTGCTCT 4

RESULT 4
US-10-032-585-1769
; Sequence 1769, Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 1769
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-1769

Query Match 51.3%; Score 15.4; DB 15; Length 43;
Best Local Similarity 76.0%; Pred. No. 6e+03;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 5 TTGCGGCAAGAAATTTCTGT 29
|||||
DB 1 TTACGACAGACAAATTTGAACTAT 25

RESULT 5
US-09-908-975-30222
; Sequence 30222, Application US/09908975
; Publication No. US20030165843A1
; GENERAL INFORMATION:
; APPLICANT: SHOSHAN, Avi
; APPLICANT: WASSERMAN, Alon
; APPLICANT: MINTZ, Eli
; APPLICANT: MINTZ, Liat
; APPLICANT: FAIGLER, Simchon
; TITLE OF INVENTION: OLIGONUCLEOTIDE LIBRARY FOR DETECTING RNA TRANSCRIPTS AND SPLICE
; FILE REFERENCE: 36688-0005
; CURRENT APPLICATION NUMBER: US/09/908,975

US-10-03

; CURRE.

```
Query Match      50.0%; Score 15; DB 16; Length 41;
Best Local Similarity 72.0%; Pred. No. 9e-03;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 38 TAATTACAGCAATATGATGTTTTTC 14

RESULT 10
US-10-027-632-51852
; Sequence 51852, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51852
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51852

Query Match      50.0%; Score 15; DB 13; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 11
US-10-027-632-51860
; Sequence 51860, Application US/10027632
; Publication No. US20020198371A1
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
```

```
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match      50.0%; Score 15; DB 13; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 12
US-10-027-632-51852
; Sequence 51852, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
; CURRENT FILING DATE: 2002-04-30
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51852
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51852

Query Match      50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAAGAAGAAATTGTTTC 26
    ||||| ||||| ||||| ||||| |||||
Db 10 TAATGAGGCAATAGAAACSAATTC 34

RESULT 13
US-10-027-632-51860
; Sequence 51860, Application US/10027632
; Publication No. US20030204075A9
; GENERAL INFORMATION:
; APPLICANT: Wang, David G.
; TITLE OF INVENTION: Identification and Mapping of Single Nucleotide
; FILE REFERENCE: 108827.129
; CURRENT APPLICATION NUMBER: US/10/027,632
```

```

; CURRENT FILING DATE: 2002-04-30
; PRIOR APPLICATION NUMBER: US 60/218,006
; PRIOR FILING DATE: 2000-07-12
; PRIOR APPLICATION NUMBER: US 60/198,676
; PRIOR FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: US 60/193,483
; PRIOR FILING DATE: 2000-03-29
; PRIOR APPLICATION NUMBER: US 60/185,218
; PRIOR FILING DATE: 2000-02-24
; PRIOR APPLICATION NUMBER: US 60/167,363
; PRIOR FILING DATE: 1999-11-23
; PRIOR APPLICATION NUMBER: US 60/156,358
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/146,002
; PRIOR FILING DATE: 1999-08-09
; NUMBER OF SEQ ID NOS: 325720
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 51860
; LENGTH: 68
; TYPE: DNA
; ORGANISM: Human
US-10-027-632-51860

Query Match 50.0%; Score 15; DB 15; Length 68;
Best Local Similarity 72.0%; Pred. No. 1e-04;
Matches 18; Conservative 1; Mismatches 6; Indels 0; Gaps 0;

QY 2 TAATTGGCGCAAGAGAAATTGTTTC 26
Db 10 TAAATGAGGCATAAGAACATTC 34

RESULT 14
US-10-125-994A-68
; Sequence 68; Application US/10125994A
; Publication No. US20030203427A1
; GENERAL INFORMATION:
; APPLICANT: Koike, Chihito
; TITLE OF INVENTION: ALPHA 1.3-GALACTOSYLTRANSFERASE GENE AND PROMOTER
; FILE REFERENCE: 206779
; CURRENT APPLICATION NUMBER: US/10/125,994A
; CURRENT FILING DATE: 2002-04-19
; PRIOR APPLICATION NUMBER: PCT/US00/29139
; PRIOR FILING DATE: 2000-10-20
; PRIOR APPLICATION NUMBER: US 60/227,951
; PRIOR FILING DATE: 2000-09-25
; PRIOR APPLICATION NUMBER: US 60/161,092
; PRIOR FILING DATE: 1999-10-22
; NUMBER OF SEQ ID NOS: 96
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 68
; LENGTH: 35
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer for identifying murine exons 2 and 3
US-10-125-994A-68

Query Match 49.3%; Score 14.8; DB 15; Length 35;
Best Local Similarity 73.1%; Pred. No. 1.1e-04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 5 TTGCGGCAAGAGAAATTGTTCTGTC 30
Db 6 TTGAGGATCCCAAGACTTGTCTGAC 31

RESULT 15
US-10-032-585-1755/c
; Sequence 1755; Application US/10032585
; Publication No. US20030180953A1
; GENERAL INFORMATION:
; APPLICANT: Terry, Roemer D.
; APPLICANT: Bo, Jiang
; APPLICANT: Charles, Boone
; APPLICANT: Howard, Bussey
; TITLE OF INVENTION: Gene Disruption Methodologies for Drug Target Discovery
; FILE REFERENCE: 10182-005-999
; CURRENT APPLICATION NUMBER: US/10/032,585
; CURRENT FILING DATE: 2001-12-20
; NUMBER OF SEQ ID NOS: 8000
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 1755
; LENGTH: 43
; TYPE: DNA
; ORGANISM: Candida albicans
US-10-032-585-1755

Query Match 49.3%; Score 14.8; DB 15; Length 43;
Best Local Similarity 88.9%; Pred. No. 1.1e-04;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 12 AAGAAGAAATTTGTTCTGT 29
Db 42 AAGAAGAACTTGTCTTGT 25

Search completed: November 5, 2004, 17:21:01
Job time : 347 secs

```


GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: November 5, 2004, 15:28:19 ; Search time 2315 Seconds
(without alignments)

472.221 Million cell updates/sec

Title: US-09-890-363-1

Perfect score: 30

Sequence: 1 gtaattcgccgaagaattgtttctgtc 30

Scoring table: IDENTITY_NUC

Gapop 10.0 , Gapext 1.0

Searched: 32822875 seqs, 18219865908 residues

Total number of hits satisfying chosen parameters: 389094

Minimum DB seq length: 0

Maximum DB seq length: 75

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database :

E8T.*

1: gb_est1.*

2: gb_est2.*

3: gb_hic.*

4: gb_est3.*

5: gb_est4.*

6: gb_est5.*

7: gb_est6.*

8: gb_gss1.*

9: gb_gss2.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	ID	Description
1	17.4	58.0	37	A2333195	A2333195 1M0062G09
2	15.6	52.0	70	T87927	T87927 ye08c07.r1
3	15.4	51.3	62	A1024389	A1024389 r8421a45
4	15.4	51.3	67	AA591826	AA591826 vi49e12.r
5	15.4	51.3	70	CD881894	CD881894 F1.104K17
6	15.4	51.3	70	BH865903	BH865903 SALK.1000
7	15.4	51.3	75	AU014056	AU014056 AU014056
8	15.2	50.7	39	BH209815	BH209815 SALK.0561
9	15.2	50.7	49	AU599937	AU599937 Arabidops
10	15.2	50.7	74	AA704411	AA704411 zj21h01.s
11	15.2	50.7	74	CF853347	CF853347 DSMC008xH
12	15.0	50.0	41	BH856306	BH856306 SALK.0799
13	15.0	50.0	58	AA554039	AA554039 nk95G03.s
14	15.0	50.0	75	BM341762	BM341762 fw52e08.y
15	14.8	49.3	39	B2535115	B2535115 601231231
16	14.8	49.3	44	AA622559	AA622559 1M0459F24
17	14.8	49.3	59	BZ769592	BZ769592 SALK.1424
18	14.8	49.3	60	AA388795	AA388795 vb25C07.r
19	14.8	49.3	61	A1829969	A1829969 wj85b06.x
20	14.8	49.3	63	N23930	N23930 Yx85a12.s1
21	14.6	48.7	52	BF633547	BF633547 NF057G03D
22	14.6	48.7	54	BH812420	BH812420 SALK.0617
23	14.6	48.7	62	CG667820	CG667820 OST462327
24	14.6	48.7	64	BI097338	BI097338 SWO3MCAAM

C 25	14.6	48.7	67	9	CC795622	CC795622 SALK.0875
26	14.6	48.7	69	6	CD028982	CD028982 mgns007xf
27	14.6	48.7	72	6	BJ057828	BJ057828 BJ057828
28	14.6	48.7	73	5	EX897533	EX897533 EX897533
29	14.6	48.7	73	6	CB832531	CB832531 SWBmfCAV
30	14.6	48.7	73	9	CG495277	CG495277 OST34591
31	14.6	48.7	74	7	CN862695	CN862695 000903AAL
32	14.6	48.7	75	2	AW247813	AW247813 2820447.3
33	14.4	48.0	42	1	AU268709	AU268709 AU268709
34	14.4	48.0	45	6	CA967668	CA967668 CcLQ03a10
35	14.4	48.0	68	1	AV852289	AV852289 AV852289
36	14.4	48.0	68	8	AZ521506	AZ521506 1005030C0
37	14.4	48.0	73	5	BUR70927	BUR70927 C021E02.P
38	14.4	48.0	74	8	AZ576247	AZ576247 AST-TD14S
39	14.4	48.0	75	6	CD744649	CD744649 IRB17.A12
40	14.2	47.3	37	4	BJ066419	BJ066419 BJ066419
41	14.2	47.3	50	8	BZ664415	BZ664415 SALK.0710
42	14.2	47.3	50	8	BZ664418	BZ664418 SALK.0711
43	14.2	47.3	52	8	AZ694935	AZ694935 TE-389-3
44	14.2	47.3	54	2	BF450060	BF450060 maa46c07.
45	14.2	47.3	54	8	BZ761965	BZ761965 SALK_0837

ALIGNMENTS

RESULT 1
AZ333195/c
LOCUS
DEFINITION
1M0062G09F Mouse 10kb plasmid UUGC1M library Mus musculus genomic
clone UUGC1M0062G09 F, genomic survey sequence.

ACCESSION
AZ333195

VERSION
AZ333195.1 GI:10397573

KEYWORDS
GSS.

SOURCE
Mus musculus (house mouse)

ORGANISM
Mus musculus

REFERENCE
1 (bases 1 to 37)

AUTHORS
Dunn,D., Aoyagi,A., Barber,M., Beacorn,T., Duval,B., Hamil,C.,

Islan,H., Longacre,S., Mahmoud,M., Meenen,E., Pedersen,T.,

Reilly,M., Rose,M., Rose,R., Stokes,R., Tingey,A., von

Niederhausern,A. and Wright,D.,Weiss,R.

Mouse whole genome scaffolding with paired end reads from 10kb

plasmid inserts

Unpublished (2000)

CONTACT: Robert B. Weiss

University of Utah

University of Utah

Rm. 308, Biomedical Polymers Research Bldg., 20 S. 2030 E., SLC, UT

84112, USA

Tel: 801 585 5606

Fax: 801 585 7177

Email: ddunn@genetics.utah.edu

Insert Length: 10000 Std Error: 0.00

Plate: 0062 row: G column: 09

Seq primer: CGTTGTAACGACGCGCCAGT

Class: plasmid ends

High quality sequence step: 37.

Location/Qualifiers

1..37

/organism="Mus musculus"

/mol_type="genomic DNA"

/strain="C57BL/6J"

/db_xref="taxon:10090"

/clone="UUGC1M0062G09"

/sex="Male"

/lab_host="E. Coli strain XL10-Gold, TI-resistant, F-"

/clone_lib="Mouse 10kb plasmid UUGC1M library"

/notes="Vector: PWD42nv; Purified genomic DNA from M.

musculus C57BL/6J (male) was obtained from the Jackson

Laboratory Mouse DNA Resource

(http://www.jax.org/resources/documents/dnares/). The DNA


```

Db      23  GGAGTTGTGGGACAGACAAATTTATT 47
|||||
AA591826 67 bp mRNA linear EST 16-SEP-1997
LOCUS vi49612.r1 Beddington mouse embryonic region Mus musculus cDNA
DEFINITION clone IMAGE:907150.5, similar to gb:U61399 Mouse F52 mRNA for a
novel protein (MOUSE), mRNA sequence.
ACCESSION AA591826
VERSION AA591826.1 GI:2405489
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
REFERENCE 1 (bases 1 to 67)
AUTHORS Marra,M., Hillier,L., Allen,M., Bowles,M., Dietrich,N., Dubuque,T.,
Geisel,S., Kucaba,T., Lacy,M., Le,M., Martin,J., Morris,M.,
Schellenberg,K., Steptoe,M., Tan,F., Underwood,K., Moore,B.,
Theising,B., Wylie,T., Lennon,G., Soares,B., Wilson,R. and
Waterston,R.
TITLE The WashU-HMI Mouse EST Project
JOURNAL Unpublished (1996)
COMMENT Contact: Marra M/Mouse EST Project
WashU-HMI Mouse EST Project
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: mouseest@wustl.wustl.edu
This clone is available royalty-free through LLNL; contact the
IMAGE Consortium (info@image.llnl.gov) for further information.
MGF:527814
Trace considered overall poor quality
Putative full length read
vector to vector length is 111
Seq primer: -28ml3 rev1 ET from Amersham
High quality sequence stop: 1.
FEATURES
Location/Qualifiers
1..67
/organism="Mus musculus"
/mol_type="mRNA"
/strain="C57BL/6 x DBA"
/db_xref="taxon:10090"
/clone="IMAGE:907150"
/sex="pooled"
/tissue_type="embryo"
/dev_stage="7.5dpc"
/lab_host="DH12S"
/clone_lib="Beddington mouse embryonic region"
/note="Organ: whole embryo; Vector: pCMV-SPORT, Site_1:
Salt; Site 2: NotI; Cloned unidirectionally. Primer:
Oligo dr. Gastrulating embryos were collected at 7.5dpc
from C57BL/6 x DBA matings, excluding embryos that had
developed head folds and all extraembryonic tissues.
Average insert size: 1.3 kb (range: 0.5 - 3.0 kb).
Referenced in Development 121, 2479-2489 (1995)".

RESULT 6
Query Match 51.3%; Score 15.4; DB 1; Length 67;
Best Local Similarity 76.0%; Pred. No. 4.7e+04;
Matches 19; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 1 GTAATTGCGGCAAGAAATTTGTTT 25
|||||
Db 31 GTAAATCCGGGTGGGAAGATGTTT 7
|||||

RESULT 5
CD881894 70 bp mRNA linear EST 14-JUL-2003
LOCUS CD881894
DEFINITION F1.104K17F010329 F1 Triticum aestivum cDNA clone F1104K17, mRNA
sequence.
ACCESSION CD881894
VERSION CD881894.1 GI:32642165
KEYWORDS EST.
SOURCE Triticum aestivum (bread wheat)
ORGANISM Triticum aestivum
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;
Poideae; Triticeae; Triticum.
REFERENCE 1 (bases 1 to 70)
AUTHORS Genoplate, a major partnership french program in plant genomics
JOURNAL Unpublished (2003)
COMMENT Contact: Genoplate
Genoplate
93, rue Henri Rochefort 91025 EVRY CEDEX France
Tel: 33 1 69 47 54 00
Fax: 33 1 69 47 54 10
This sequence has been generated in the framework of the french
plant genomics programme 'Genoplate' (http://www.genoplate.com
and http://genoplate-info.infobiogen.fr).
FEATURES
Location/Qualifiers
1..70
/organism="Triticum aestivum"
/mol_type="mRNA"
/cultivar="recital"
/db_xref="taxon:4565"
/clone="F1104K17"
/tissue_type="leaf one"
/clone_lib="F1"

ORIGIN
Query Match 51.3%; Score 15.4; DB 6; Length 70;
Best Local Similarity 94.1%; Pred. No. 4.8e+04;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 14 GAAGAATTGTTTCTGTC 30
|||||
Db 14 GAGGAATTGTTTCTGTC 30
|||||

RESULT 6
BH865903/c 70 bp DNA linear GSS 05-AUG-2002
LOCUS SALK_100053 Arabidopsis thaliana TDNA insertion lines Arabidopsis
thaliana genomic clone SALK_100053, genomic survey sequence.
ACCESSION BH865903
VERSION BH865903.1 GI:22101801
KEYWORDS GSS.
SOURCE Arabidopsis thaliana (thale cress)
ORGANISM Arabidopsis thaliana
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; eudicotyledons; core eudicots;
rosids; eurosids II; Brassicales; Brassicaceae; Arabidopsids.
REFERENCE 1 (bases 1 to 70)
AUTHORS Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shinn,P., Zimmerman,J. and Ecker,J.R.
TITLE A Sequence-indexed Library of Insertion Mutations in the
Arabidopsis Genome
JOURNAL Unpublished (2001)
COMMENT Contact: Joseph R. Ecker
Salk Institute Genomic Analysis Laboratory (SIGNAL)
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
Tel: 858 453 4100 x1752
Fax: 858 558 6379
Email: ecker@salk.edu
This is single pass sequence recovered from the left border of
TDNA. This sequence lies within an annotated exon of At4g32010.
Class: TDNA tagged.
Location/Qualifiers

```

```

RESULT 8
BH0909815/c
LOCUS
DEFINITION
ABRIDGED THALIANA GENOMIC CLONE SALK_056115.47.35.X, GENOMIC
SURVEY SEQUENCE.
ACCESSION
BH0909815
VERSION
BH0909815.1
KEYWORDS
GSS
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Eukaryota; Viridiplantae; Magnoliophyta; Eudicotyledons; Core
Eudicots;
Spermatophyta; Magnoliophyta; Eudicotyledons; Core Eudicots;
Rosids; Eurosids II; Brassicales; Brassicaceae; Arabidopsi
1 (bases 1 to 39)
REFERENCE
Alonso,J.M., Leisse,T.J., Barajas,P., Chen,H., Cheuk,R.,
Gadrinab,C., Jeske,A., Karnes,M., Kim,C.J., Parker,H., Prednis,L.,
Shinn,P., Zimmerman,J. and Ecker,J.R.
AUTHORS
A Sequence-Indexed Library of Insertion Mutations in the
Arabidopsis Genome
PUBLISHED
2001
CONTACT
Contact: Joseph R. Ecker
INSTITUTION
Salk Institute Genomic Analysis Laboratory (SIGAL)
ADDRESS
The Salk Institute for Biological Studies
10010 N. Torrey Pines Road, La Jolla, CA 92037, USA
TEL
Tel: 858 453 4100 x1752
FAX
Fax: 858 536 6379
EMAIL
Email: ecker@salk.edu
NOTES
This is single pass sequence recovered from the left border of
TDNA.
CLASS
Class: TDNA tagged.
FEATURES
Location/Qualifiers
1..39
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/scotype="Col-0"
/db_xref="taxon:3702"
/clone="SALK_056115.47.35.X"
/clone_lib="Arabidopsis thaliana TDNA insertion lines"
/notes="PCR was performed on Arabidopsis thaliana lines
each of which contains one or more TDNA insertion
elements. The resultant fragment for each line was
directly sequenced to determine the genomic sequence at
the site of insertion. Details of the protocols used can
be found at http://signal.salk.edu/tdna\_protocols.html"
ORIGIN
Query Match 50.7%; Score 15.2; DB 8; Length 39;
Best local similarity 71.4%; Pred. No. 5,4e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;
QY
2 TAATGGCGCAAGAGAAATGTTCTGT 29
|||||
|||||
|||||
|||||
DB
37 TAATTACATAAGATAATATGTTCTGT 10
RESULT 9
AJ599937
LOCUS
DEFINITION
Arabidopsis thaliana T-DNA flanking sequence, left border, clone
496H09, genomic survey sequence.
ACCESSION
AJ599937
VERSION
AJ599937.1
KEYWORDS
GSS; left border; T-DNA flanking sequence.
SOURCE
Arabidopsis thaliana (thale cress)
ORGANISM
Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;
Spermatophyta; Magnoliophyta; Eudicotyledons; Core Eudicots;
Rosids; Eurosids II; Brassicales; Brassicaceae; Arabidopsi
1
REFERENCE
Brunaud,V., Balzergue,S., Dubreucq,B., Aubourg,S., Samson,F.,
Chauvin,S., Bechtold,N., Cruaud,C., DeRose,R., Pellier,G.,
Lennier,C., Caboche,M. and Leclercq,A.

```

T-DNA integration into the Arabidopsis genome depends on sequences of pre-insertion sites

EMBO Rep. 3 (12), 1152-1157 (2002)

22363535
PUBMED
12446565

REFERENCE
2 (bases 1 to 49)

AUTHORS
Balzergue,S.

JOURNAL
Submitted (23-OCT-2003) Balzergue S., UMRGV, INRA/CNRS, 2 rue Gaston Cremieux, 31057 Evry cedex, FRANCE

COMMENT
PCR was performed on DNA from transformants of Arabidopsis thaliana plants from INRA (Versailles). The DNA fragment(s) resulting from the PCR were directly sequenced from the left or the right border to determine the genomic sequence flanking the insertion. T-DNA derived sequences were removed. Information to order the corresponding mutant line and a link to a database providing a graphical display of the insertion site are available at <http://dbsgap.versailles.inra.fr/publiclines/>. This sequence has been generated in the framework of the French plant genomics program 'Genoplante' (<http://www.genoplante.com> and <http://genoplante-info.infobiogen.fr>).

FEATURES
Location/Qualifiers
1..49
/organism="Arabidopsis thaliana"
/mol_type="genomic DNA"
/cultivar="Wassiljewskij4"
/db_xref="taxon:3702"
/clone="496H09"
/clone_lib="Arabidopsis thaliana T-DNA insertion lines"
misc_feature
1..49 T-DNA flanking sequence
/note="T-DNA left border"

ORIGIN
Query Match 50.7%; Score 15.2; DB 9; Length 49;
Best Local Similarity 71.4%; Pred. No. 5.6e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 2 TAATTGGCGCAGAGAAATGTTCTGT 29
|||||
Db 15 TAGTTGGCAATGTAGATCCTTTTGT 42

RESULT 10
-AA704411/c
LOCUS
DEFINITION
zj21h01.sl Soares_fetal_liver_spleen.INFLS_S1 Homo sapiens cDNA clone IMAGE:450961 3', mRNA sequence.

ACCESSION
AA704411
KEYWORDS
SOURCE
Homo sapiens (human)

ORGANISM
Homo sapiens

REFERENCE
AUTHORS
Hillier,L., Allen,M., Bowles,L., Dubuque,T., Geisels,G., Jost,S., Krizman,D., Kucaba,T., Lay,M., Le,N., Lennon,G., Marra,M., Martin,J., Moore,B., Schellenberg,K., Stepcoe,M., Tan,F., Theising,B., White,Y., Wylie,T., Waterston,R. and Wilson,R.

TITLE
JOURNAL
COMMENT
WashU-NCI human EST Project
Unpublished (1997)
Contact: Wilson RK
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108
Tel: 314 286 1800
Fax: 314 286 1810
Email: est@watson.wustl.edu
This clone is available royalty-free through INL; contact the IMAGE Consortium (info@image.lnlnl.gov) for further information.
Seq primer: -40m13 fwd ET from Amersham
High quality sequence stop: 52.
Location/Qualifiers

1..74
/organism="Homo sapiens"
/mol_type="mRNA"
/db_xref="GDB:1387317"
/db_xref="taxon:9606"
/clone="IMAGE:450961"
/sex="male"
/dev_stage="20 week post conception fetus"
/lab_host="DH10B (ampicillin resistant)"
/clone_lib="Soares_fetal_liver_spleen.INFLS_S1"
/note="Organ: Liver and Spleen; Vector: pT7T3D (Pharmacia) with a modified polylinker; Site 1: Pac 1; Site 2: Eco RI; This is a subcloned version of the original Soares fetal liver spleen INFLS library. 1st strand cDNA was primed with a Pac 1 - oligo(dT) primer [5'-TTTTTTTTTTT 3']
AACGGAAGATTAATTAAGATCTTTTCTTTTCTTTT 31'
double-stranded cDNA was ligated to Eco RI adaptors (Pharmacia), digested with Pac 1 and cloned into the Pac 1 and Eco RI sites of the modified pT7T3 vector. Library went through one round of normalization. Library constructed by Bento Soares and M.Fatima Bonaldo."

Query Match 50.7%; Score 15.2; DB 1; Length 74;
Best Local Similarity 71.4%; Pred. No. 5.9e+04;
Matches 20; Conservative 0; Mismatches 8; Indels 0; Gaps 0;

Qy 3 AATTGGCGCAGAGAAATGTTCTGTCTC 30
|||||
Db 34 ATTATGGCAATATAAATTTTCTGTCTC 7

RESULT 11
CF853347
LOCUS
DEFINITION
CF853347.1 74 bp mRNA linear EST 30-OCT-2003
psMC008H16f USDA-IPAFS:Expression of Phytophthora sojae genes during infection and propagation_SMC Phytophthora sojae cDNA clone SMC008H16 5', mRNA sequence.

ACCESSION
CF853347
VERSION
KEYWORDS
SOURCE
Phytophthora sojae
Phytophthora sojae
Eukaryota; stramenopiles; Oomycetes; Pythiales; Pythiaceae;
Phytophthora.
1 (bases 1 to 74)
Tyler,B. Not Published
Unpublished (2003)
Contact: Tyler B
Tyler lab
VBI
1880 Pratt Dr., Blacksburg, VA 24061, USA
Tel: 540-231-7318
Email: bmyler@vt.edu
PCR Primers
FORWARD: M13 reverse 17mer at 5' end
BACKWARD: M13 reverse 17mer at 5' end
Plate: 008 row: H column: 16
Seq primer: M13 reverse 17mer at 5' end
High quality sequence stop: 74.
Location/Qualifiers

1..74
/organism="Phytophthora sojae"
/mol_type="mRNA"
/db_xref="taxon:67593"
/clone="SMC008H16"
/tissue_type="mycelium"
/cell_line="P6497"
/dev_stage="synthetic medium"
/lab_host="USDA-IPAFS:Expression of Phytophthora sojae genes during infection and propagation_SMC"

FEATURES
source

TITLE
JOURNAL
COMMENT
WashU Zebrafish EST Project 1998
Unpublished (1998)
Contact: Stephen L. Johnson
Washington University School of Medicine
4444 Forest Park Parkway, Box 8501, St. Louis, MO 63108, USA
Tel: 314 286 1800
Fax: 314 286 1810
Email: zbrafish@wustl.wustl.edu
cDNA Library construction by: Joe Barnes and Steve Johnson. DNA
Sequencing by: Washington University Genome Sequencing Center Clone
distribution: Research Genetics web address:
<http://www.researchgenetics.com/>
Putative full length read
The vector to vector length is 76
Seq primer: T3 ET from Amersham.
Location/Qualifiers

FEATURES

source

1. .75
/organism="Danio rerio"
/mol_type="mRNA"
/strain="SJD"
/db_xref="taxon:7955"
/clone="IMAGE:5568470"
/tissue_type="embryo, day 3"
/lab_host="DH10B"
/clone_lib="Zebrafish SJD day 3 embryo"
/note="Vector: pAMPI. Site 1: EcoRI; Site 2: NotI; First
strand cDNA synthesis was primed using oligo-dT on
magnetic beads with an additional primer
5'-ggcgccgtatcagctactactatag-3'. Second strand
synthesis was a 3-cycle PCR using the primers
5'-ggcgccgtatcagctactactatag-3' and
5'-aagcagtggttaacacgcagctactt-tttttttttt-3'. cDNA
was subsequently amplified in a 7-cycle PCR with the
following primers: 5'-ggcgccgtatcagctactactatag-3' and
5'-aagcagtggtt-aacacgcag. Deoxy-UMP adaptors were added in
a third PCR (5 cycles) and the primers
5'-caucaucauagcgcgtatcagctactactataggg-3' and
5'-caucaucauagcagctgtgtaacacgcagctac-3'. Ends were
treated with uracil DNA glycosylase and product with 3'
overhangs was annealed to complementary ends of pAMPI.
Insert can be excised using EcoRI and NotI. Library
constructed by Joe Barnes and Steve Johnson (Washington
University)."

ORIGIN

Query Match 50.0%; Score 15; DB 4; Length 75;
Best Local Similarity 78.3%; Pred. No. 7.2e+04;
Matches 18; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

Dy 3 AATTGCGGCAAGAGAAATTGTTT 25
|||||
Db 12 AATTAGAAAAGAGAGATTGTTT 34
|||||

RESULT 15
BE535115
LOCUS
DEFINITION 601231231F1 NCI_CGAP_Mam6 Mus musculus cDNA clone IMAGE:3595207 5',
mRNA sequence.
39 bp mRNA linear EST 09-AUG-2000
BE535115
ACCESSION BE535115
VERSION BE535115.1 GI:9763760
KEYWORDS EST.
SOURCE Mus musculus (house mouse)
ORGANISM Mus musculus
Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus.
1 (bases 1 to 39)
NIH-MSC <http://mgc.nci.nih.gov/>.
National Institutes of Health, Mammalian Gene Collection (MGC)
UNPUBLISHED (1999)
AUTHORS
TITLE
COMMENT
Contact: Robert Strausberg, Ph.D.
Email: cgapbs-r@mail.nih.gov
Tissue Procurement: Jeffrey Green M.D.

cDNA Library Preparation: Life Technologies, Inc.
cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)
DNA Sequencing by: Incyte Genomics, Inc.
Clone distribution: MGC clone distribution information can be
found through the I.M.A.G.E. Consortium/LLNL at:
<http://image.llnl.gov>
Plate: LLAM8770 row: n column: 08
High quality sequence stop: 37.
Location/Qualifiers

FEATURES

source

1. .39
/organism="Mus musculus"
/mol_type="mRNA"
/strain="FVB/N"
/db_xref="taxon:10090"
/clone="IMAGE:3595207"
/sex="female, virgin"
/tissue_type="infiltrating ductal carcinoma"
/dev_stage="5 months"
/lab_host="DH10B"
/clone_lib="NCI CGAP Mam6"
/note="Organ: mammary; Vector: pCMV-SPORT6; Site 1: SalI;
Site 2: NotI; Cloned unidirectionally. Primer: Oligo dT.
Library constructed by Life Technologies. Investigator
providing samples: Jeffrey Green, M.D., NIH"

ORIGIN

Query Match 49.3%; Score 14.8; DB 2; Length 39;
Best Local Similarity 73.1%; Pred. No. 8.2e+04;
Matches 19; Conservative 0; Mismatches 7; Indels 0; Gaps 0;

QY 3 AATTGCGGCAAGAGAAATTGTTTCTG 28
|||||
Db 5 AATAAAGGCAAGAAAATTGCTGATG 30
|||||

Search completed: November 5, 2004, 17:13:58
Job time : 2324 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM protein - protein search, using sw model

Run on: November 5, 2004, 20:41:18 ; Search time 43 Seconds
(without alignments)
157.312 Million cell updates/sec

Title: US-09-882-434A-1
Perfect score: 551
Sequence: 1 MASTKLFPSVITVMVLIAMA.....FGSARACNPFQKSIQIC 102

Scoring table: BLOSUM62
Gapop 10.0 , Gapext 0.5

Searched: 478139 seqs, 66318000 residues

Total number of hits satisfying chosen parameters: 478139

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Issued Patents AA.*

- 1: /cgn2_6/ptodata/1/iaa/5A.COMB.pep.*
- 2: /cgn2_6/ptodata/1/iaa/5B.COMB.pep.*
- 3: /cgn2_6/ptodata/1/iaa/6A.COMB.pep.*
- 4: /cgn2_6/ptodata/1/iaa/6B.COMB.pep.*
- 5: /cgn2_6/ptodata/1/iaa/PTUS.COMB.pep.*
- 6: /cgn2_6/ptodata/1/iaa/backfiles1.pep.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match	Length	DB ID	Description
1	75.5	13.7	486	4	US-08-169-613A-2
2	75.5	13.7	486	4	US-08-622-191-8
3	74.5	13.5	486	1	US-07-872-678A-48
4	74.5	13.5	908	4	US-08-714-741-44
5	71	12.9	1280	4	US-09-672-810-2
6	71	12.9	1283	4	US-09-672-810-4
7	70	12.7	365	4	US-09-252-991A-30166
8	69	12.5	491	4	US-09-248-796A-17049
9	69	12.5	1280	4	US-09-672-810-7
10	69	12.5	1280	4	US-09-672-725C-4
11	69	12.5	1280	4	US-10-044-671-2
12	69	12.5	1281	4	US-09-672-725C-2
13	69	12.5	1281	4	US-09-672-725C-23
14	69	12.5	1281	4	US-09-672-725C-25
15	69	12.5	1281	4	US-09-672-725C-27
16	68	12.3	1280	2	US-08-583-276-19
17	68	12.3	1280	2	US-08-752-447-2
18	68	12.3	1280	3	US-09-316-167-2
19	68	12.3	1280	4	US-09-767-594-2
20	68	12.3	1280	4	US-09-672-810-5
21	68	12.3	1280	4	US-09-397-233-2
22	68	12.3	1280	4	US-09-672-725C-7
23	68	12.3	1280	6	5206352-4
24	67.5	12.3	312	4	US-09-252-991A-19374
25	67.5	12.3	459	4	US-09-328-352-4648
26	67.5	12.3	902	1	US-08-701-846-2
27	66	12.0	115	4	US-09-252-991A-28403

28 65 11.8 730 4 US-09-107-532A-4752 Sequence 4752, Ap
29 64.5 11.7 139 4 US-09-252-991A-19245 Sequence 19245, A
30 64.5 11.7 486 4 US-08-622-191-7 Sequence 7, Appli
31 64 11.6 1576 4 US-09-562-702A-24 Sequence 24, Appl
32 64 11.6 1576 4 US-09-561-818A-24 Sequence 24, Appl
33 64 11.6 1584 4 US-09-562-702A-28 Sequence 28, Appl
34 64 11.6 1809 4 US-09-562-702A-22 Sequence 22, Appl
35 64 11.6 1809 4 US-09-561-818A-22 Sequence 22, Appl
36 64 11.6 1609 4 US-09-538-092-900 Sequence 900, App
37 64 11.6 1617 4 US-09-562-702A-26 Sequence 26, Appl
38 63.5 11.5 1019 1 US-08-296-014A-4 Sequence 4, Appli
39 63.5 11.5 1019 2 US-08-596-405-4 Sequence 4, Appli
40 63.5 11.5 1019 2 US-08-877-620-4 Sequence 4, Appli
41 63.5 11.5 1019 4 US-09-287-368-4 Sequence 4, Appli
42 63.5 11.5 1019 4 US-09-626-793-4 Sequence 4, Appli
43 63.5 11.5 1083 1 US-08-296-014A-2 Sequence 2, Appli
44 63.5 11.5 1083 2 US-08-596-405-2 Sequence 2, Appli
45 63.5 11.5 1083 2 US-08-877-620-2 Sequence 2, Appli

ALIGNMENTS

RESULT 1
US-08-169-613A-2
; Sequence 2, Application US/08169613A
; Patent No. 6486380
; GENERAL INFORMATION:
; APPLICANT: Epstein, Paul
; TITLE OF INVENTION: Pancreatic B Cell Hexokinase Transgene
; FILE REFERENCE: P0044US0
; CURRENT APPLICATION NUMBER: US/08/169,613A
; CURRENT FILING DATE: 1993-12-17
; NUMBER OF SEQ ID NOS: 4
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2
; LENGTH: 486
; TYPE: PRT
; ORGANISM: Yeast
US-08-169-613A-2

Query Match 13.7%; Score 75.5; DB 4; Length 486;

Best Local Similarity 30.2%; Pred. No. 1.7; Indels 31; Gaps 6;

Matches 29; Conservative 9; Mismatches 27;

QY 8 FSVITVM---LIAMASEMVGSAFTVMSGPCNNRAERYSKGCSAIHQKGYDFSYTG 64
DB 369 FGINTVQERKILRLSELIGA-----RAELSVCGIAICQKEGYK---TG 412
QY 65 QTAALYNQAGCGSVAHTRF-GSSARACNP-----FGW 95
DB 413 HIAA-----DGSVYNRYPGFKEAANKADIYGW 441

RESULT 2
US-08-622-191-8
; Sequence 8, Application US/08622191A
; Patent No. 6632602
; GENERAL INFORMATION:
; APPLICANT: Sheen, Jen
; APPLICANT: Jang, Jyan-Chyun
; TITLE OF INVENTION: PLANT SUGAR SENSORS AND USES THEREOF
; FILE REFERENCE: 00786/307001
; CURRENT APPLICATION NUMBER: US/08/622,191A
; CURRENT FILING DATE: 1996-03-25
; NUMBER OF SEQ ID NOS: 13
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 8
; LENGTH: 486
; TYPE: PRT
; ORGANISM: Saccharomyces cerevisiae
US-08-622-191-8

us-09-882-434a-1-rai

Mon Nov 8 15:44:32 2004

Query Match 13.7%; Score 75.5; DB 4; Length 486;
 Best Local Similarity 30.2%; Pred. No. 1.7;
 Matches 29; Conservative 9; Mismatches 27; Indels 31; Gaps 6;
 QY 8 FSVITVM---LIAMSEVNGSAFTVWSPGNNRAERYSKGCSAIHKGKGYDFSVTG 64
 Db 369 FGINTTVQERKLIRLSELIGA-----RAALSVCGIAAICOKRGYK---TG 412
 QY 65 QTAALYNQACSGVAHTRP-GSSARACNP-----FGW 95
 Db 413 HIAA-----DGSVNRYPGFKEKAAALKDIYGH 441

RESULT 3
 US-07-872-678A-48
 ; Sequence 48; Application US/07872678A
 ; Patent No. 5541060
 ; GENERAL INFORMATION:
 ; APPLICANT: Bell, Graeme, et al.
 ; TITLE OF INVENTION: DETECTION OF EARLY-ONSET
 ; TITLE OF INVENTION: NON-INSULIN-DEPENDENT DIABETES MELLITUS
 ; NUMBER OF SEQUENCES: 48
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Arnold, White & Durkee
 ; STREET: Post Office Box 4433
 ; CITY: Houston
 ; STATE: Texas
 ; COUNTRY: USA
 ; ZIP: 77210
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: Patent in Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/07/872,678A
 ; FILING DATE: 22-APRIL-1992
 ; CLASSIFICATION: 435
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Coughlin, Daniel F.
 ; REGISTRATION NUMBER: 36,111
 ; REFERENCE/DOCKET NUMBER: ARCD016
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: 713-787-1400
 ; TELEFAX: 713-789-2679
 ; TELEX: 79-0924
 ; INFORMATION FOR SEQ ID NO: 48:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 486 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: DNA (genomic)
 ; US-07-872-678A-48

Query Match 13.5%; Score 74.5; DB 1; Length 486;
 Best Local Similarity 39.3%; Pred. No. 2.2;
 Matches 24; Conservative 4; Mismatches 18; Indels 15; Gaps 4;
 QY 40 RAERYSKGCSAIHKGKGYDFSVTGTAALYNQACSGVAHTRP-GSSARACNP---FG 94
 Db 391 RAALSVCGIAAICOKRGYK---TGHIAA-----DGSVSTRYPGFKEKAAALKDIY 440
 QY 95 W 95
 Db 441 W 441
 RESULT 4
 US-08-714-741-44
 ; Sequence 44; Application US/08714741
 ; Patent No. 6500613
 ; GENERAL INFORMATION:

APPLICANT: Briles, David E.
 APPLICANT: McDaniel, Larry S.
 APPLICANT: Swiatlo, Edwin
 APPLICANT: Yother, Janet
 APPLICANT: Crain, Marilyn J.
 APPLICANT: Hollingshead, Susan
 APPLICANT: Tart, Rebecca
 APPLICANT: Brooks-Walter, Alexis
 TITLE OF INVENTION: PNEUMOCOCCAL GENES, PORTIONS THEREOF.
 TITLE OF INVENTION: EXPRESSION PRODUCTS THEREFROM, AND USES OF SUCH GENES,
 TITLE OF INVENTION: PORTIONS AND PRODUCTS
 NUMBER OF SEQUENCES: 47
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Curtis, Morris & Safford, P.C.
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: New York
 COUNTRY: U.S.
 ZIP: 10036
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: Patent in Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/714,741
 FILING DATE: 16-SEP-1996
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Frommer Esq., William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454312-2460
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-3333
 TELEFAX: (212) 840-0712
 INFORMATION FOR SEQ ID NO: 44:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 908 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: DNA (genomic)
 US-08-714-741-44

Query Match 13.5%; Score 74.5; DB 4; Length 908;
 Best Local Similarity 34.2%; Pred. No. 4.8;
 Matches 25; Conservative 6; Mismatches 39; Indels 3; Gaps 2;
 QY 18 AMASEVNGSAFTVWSPGNNRAERYSKGCSAIHKGKGYDFSVTGTAALYNQACSG 77
 Db 240 AAACATTGAAATAATTAAGC--AAGCAAGCGAAGTTGAGACTGCTATAA-AAAGCTG 296
 QY 78 VAHTRFGSSARAC 90
 Db 297 AATTAGAAAAAAC 309

RESULT 5
 US-09-672-810-2
 ; Sequence 2; Application US/09672810
 ; Patent No. 6617450
 ; GENERAL INFORMATION:
 ; APPLICANT: STOCKER, PENNY J.
 ; APPLICANT: STEINEL-CRESPI, DOROTHY T.
 ; APPLICANT: CRESPI, CHARLES L.
 ; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
 ; FILE REFERENCE: G0307/7018
 ; CURRENT APPLICATION NUMBER: US/09/672,810
 ; CURRENT FILING DATE: 2000-09-28
 ; PRIOR APPLICATION NUMBER: US 60/156,921
 ; PRIOR FILING DATE: 1999-09-28
 ; PRIOR APPLICATION NUMBER: US 60/158,818
 ; PRIOR FILING DATE: 1999-10-12


```

; NUMBER OF SEQ ID NOS: 33142
; SEQ ID NO 30166
; LENGTH: 365
; TYPE: PRT
; ORGANISM: Pseudomonas aeruginosa
US-09-252-991A-30166

Query Match      12.7%  Score 70; DB 4; Length 365;
Best Local Similarity 27.8%  Pred. No. 5.2;
Matches 22; Conservative 7; Mismatches 46; Indels 4; Gaps 2;

QY 17 TAMASEMVNGSAFTVWGPGCNRNARERYSKCGCEATHQKGGYDFSVTGQTALYNQAGCS 76
    166 LACAADVATSAAFVAGKPGCGRSVRPAICGWEDTGTSGG---SSTGGAETLAGSRACV 222
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 166 LACAADVATSAAFVAGKPGCGRSVRPAICGWEDTGTSGG---SSTGGAETLAGSRACV 222
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
QY 77 GVA-HTRFGSSARACNPF 94
    223 DAATFAETAGACRATPDG 241
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 223 DAATFAETAGACRATPDG 241
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 8
US-09-248-796A-17049
; Sequence 17049, Application US/09248796A
; Patent No. 6747137
; GENERAL INFORMATION:
; APPLICANT: Keith Weinstock et al
; TITLE OF INVENTION: NUCLEIC ACID AND AMINO ACID SEQUENCES RELATING TO CANDID
; TITLE OF INVENTION: FOR DIAGNOSTICS AND THERAPEUTICS
; FILE REFERENCE: 107196.132
; CURRENT APPLICATION NUMBER: US/09/248,796A
; CURRENT FILING DATE: 1999-02-12
; PRIOR APPLICATION NUMBER: US 60/074,725
; PRIOR FILING DATE: 1998-02-13
; PRIOR APPLICATION NUMBER: US 60/096,409
; PRIOR FILING DATE: 1998-08-13
; NUMBER OF SEQ ID NOS: 28208
; SEQ ID NO 17049
; LENGTH: 491
; TYPE: PRT
; ORGANISM: Candida albicans
US-09-248-796A-17049

Query Match      12.5%  Score 69; DB 4; Length 491;
Best Local Similarity 39.4%  Pred. No. 9.8;
Matches 13; Conservative 8; Mismatches 12; Indels 0; Gaps 0;

QY 40 RAERYSKCCGSAIHOKGGYDFSVTGQTALYNQ 72
    398 RSARFVCGIAAICQKRGYKTAHCAADGVSYNK 430
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
DB 398 RSARFVCGIAAICQKRGYKTAHCAADGVSYNK 430
    : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : : :

RESULT 9
US-09-672-810-7
; Sequence 7, Application US/09672810
; Patent No. 6617450
; GENERAL INFORMATION:
; APPLICANT: STOCKER, PENNY J.
; APPLICANT: STEINEL-CRESPI, DOROTHY T.
; APPLICANT: CRESPI, CHARLES L.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7018
; CURRENT APPLICATION NUMBER: US/09/672,810
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,921
; PRIOR FILING DATE: 1999-09-28
; PRIOR APPLICATION NUMBER: US 60/158,818
; PRIOR FILING DATE: 1999-10-12
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 7
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Canis familiaris

```

```
US-09-672-810-7
; ORGANISM: Canis familiaris
US-10-044-671-2
Query Match      12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 335 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 394
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
|||||
Db 395 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSSC 432
|||||

RESULT 10
US-09-672-725C-4
; Sequence 4, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 4
; LENGTH: 1280
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-4

Query Match      12.5%; Score 69; DB 4; Length 1280;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 335 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 394
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
|||||
Db 395 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSSC 432
|||||

RESULT 11
US-10-044-671-2
; Sequence 4, Application US/10044671
; Patent No. 6790621
; GENERAL INFORMATION:
; APPLICANT: Washington State University Research Foundation
; APPLICANT: Mealey, Katrina
; APPLICANT: Bentjen, Steven
; TITLE OF INVENTION: MDRI VARIANTS AND METHODS FOR THEIR USE
; FILE REFERENCE: 4630-61733
; CURRENT APPLICATION NUMBER: US/10/044,671
; CURRENT FILING DATE: 2002-01-10
; PRIOR APPLICATION NUMBER: US 60/261,578
; PRIOR FILING DATE: 2001-01-12
; PRIOR APPLICATION NUMBER: US 60/314,829
; PRIOR FILING DATE: 2001-08-24
; NUMBER OF SEQ ID NOS: 10
; SOFTWARE: PatentIn version 3.1
; SEQ ID NO 2
; LENGTH: 1280
; TYPE: PRT
US-09-672-725C-4

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
|||||
Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSSC 433
|||||

RESULT 12
US-09-672-725C-2
; Sequence 2, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 2
; LENGTH: 1281
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-2

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAPTVMSGPGCNCNRAERYSKCGCSAIHQKGYD 59
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395
:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:||||:
QY 60 -----FSY-----TGQTAALYNQAGC 75
|||||
Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSSC 433
|||||

RESULT 13
US-09-672-725C-23
; Sequence 23, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 23
; LENGTH: 1281
; TYPE: PRT
US-09-672-725C-23
```

```
;
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-27

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAFTVWSGPGCNNAERYSKGCSAIHQKGGYD 59
   :|||: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395

QY 60 -----FSY-----TGQTAALYNQAGC 75
   ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGC 433
```

Search completed: November 5, 2004, 21:56:30
Job time : 45 secs

```
;
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-23

Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAFTVWSGPGCNNAERYSKGCSAIHQKGGYD 59
   :|||: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395

QY 60 -----FSY-----TGQTAALYNQAGC 75
   ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGC 433
```

RESULT 14
US-09-672-725C-25
; Sequence 25, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 25
; LENGTH: 1281
; TYPE: PRT
; ORGANISM: Canis familiaris
US-09-672-725C-25

```
Query Match      12.5%; Score 69; DB 4; Length 1281;
Best Local Similarity 25.5%; Pred. No. 32;
Matches 25; Conservative 12; Mismatches 33; Indels 28; Gaps 3;

QY 6 LFFSVITVMMLIAMASEMV-----NGSAFTVWSGPGCNNAERYSKGCSAIHQKGGYD 59
   :|||: : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 336 VFFSVLIGAFSIGQASPSIEAFANARGAAYEIFKIIDNKPSIDSYSKSGHKPDNIKGNLE 395

QY 60 -----FSY-----TGQTAALYNQAGC 75
   ||| : : : : : : : : : : : : : : : : : : : : : : : : : : : : :
Db 396 FKNVHFSYPSRKEVKILKGLNLKVQSGQTVALVGNSGC 433
```

RESULT 15
US-09-672-725C-27
; Sequence 27, Application US/09672725C
; Patent No. 6753177
; GENERAL INFORMATION:
; APPLICANT: Stocker, Penny J.
; APPLICANT: Steimel-Crespi, Dorothy T.
; APPLICANT: Crespi, Charles L.
; APPLICANT: Rief, Timothy C.
; APPLICANT: Patten, Christopher J.
; TITLE OF INVENTION: P-GLYCOPROTEINS AND USES THEREOF
; FILE REFERENCE: G0307/7017
; CURRENT APPLICATION NUMBER: US/09/672,725C
; CURRENT FILING DATE: 2000-09-28
; PRIOR APPLICATION NUMBER: US 60/156,510
; PRIOR FILING DATE: 1999-09-28
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 27

